Control of Cardiovascular Function, Disorders of Blood Flow & Blood Pressure, Hyperlipidemia & Artherosclerosis
Review of Hemodynamics Blood vessel structure, function Regulation of cardiac output Mechanisms of blood pressure regulation Disorders of blood pressure Hypertension Orthostatic hypotension Drugs that affect blood pressure Disorders of arterial circulation Hyperlipidemia, atherosclerorosis Drugs that lower LDL cholesterol
Pulmonary and  Systemic Circulation Baxter Corp. (1999)
Differences in the Two Systems PULMONARY Low pressure system (MPAP 12 mmHg) Good for gas exchange SYSTEMIC   High pressure system (MAP 90-100 mmHg) Good for distant transport, against gravity
How does blood get back to the heart? Lehne, 2009,  Pharmacology for Nursing Care,  7 th  ed., Elsevier, p 461
Principles of Blood Flow Hemodynamics Heart is an intermittent pump, blood flow is pulsatile Factors governing the function of the CV system Volume Pressure Resistance Flow
Determinants of Blood Pressure BP = CO X Peripheral vascular resistance CO = SV X HR What determines peripheral vascular resistance?
Resistance of a Tube Porth,  Pathophysiology, Concepts of Altered Health States, 7 th  ed.,  2005, Lippincott, p. 452. Also see p 322, point 2 in Porth,  Essentials Big factor!
Volume & Pressure Distribution Porth, 2007,  Essentials of Pathophysiology,  2 nd  ed., Lippincott, p. 321. Arteriolar tone determines systemic vascular resistance
Same concept from Lehne Lehne, 2009,  Pharmacology for Nursing Care,  7 th  ed., Elsevier, p 461
All Blood Vessels Have 3 Layers Intima - elastic layer Media - smooth muscle for diameter control (innervated by the SNS with alpha receptors) Externa - fibrous and connective tissue for support Porth, 2007,  Essentials of Pathophysiology,  2 nd  ed., Lippincott, p. 338
Resistance Arterioles Maintain Blood Pressure Porth, 2007,  Essentials of Pathophysiology,  2 nd  ed., Lippincott, p. 338 Arteries have abundant smooth muscle.  The diameter of the artery/arteriole is determined by the degree of contraction of the smooth muscle, which is mediated by the SNS (alpha receptors).
Blood Vessels and the  Peripheral Circulation Blood vessels are dynamic structures They constrict and relax to adjust blood flow to meet varying needs of tissues/organs The heart, brain, liver, and kidney require large continuous flow Skin, skeletal muscle require varying flow
Arteries, Arterioles Elasticity allows for stretching during systole Arterioles have abundant smooth muscle Arterioles are the major resistance vessels for circulatory system and basically determine the systemic vascular resistance Sympathetic fibers innervate arterioles cause them to constrict/relax as needed to maintain BP (alpha receptors)
Veins, Venules Collect blood from capillaries, carry back to heart Enlarge and store large quantities of blood Contract/expand to accommodate varying amounts Innervated by SNS (alpha receptors) Venous constriction can increase the preload to the heart by conducting stored blood into the vena cava
Veins Valves prevent retrograde flow Incompetent valves in venous varicosities Skeletal muscles help compress veins in “milking manner” up to heart Low pressure system – Pressure  in venules is ~10 mm Hg and in the vena cava ~0 mmHg Porth, 2007,  Essential of Pathophysiology,  2 nd  ed., Lippincott, p. 339.
Endothelial Cells Endothelial cells line all blood vessels.  They are normally quite smooth and permit laminar blood flow.  They also form a tight barrier in larger vessels, but in capillaries are more permissive of small molecules exiting and entering the vascular system.
Capillaries Single cell-thick vessels that connect arterial and venous segments Wall composed of a single layer of endothelial cells surrounded by a basement membrane In most vascular beds, capillaries have fenestrations that allow passage of water and small molecules but not large proteins. Porth, 2007,  Essentials of Pathophysiology,  2 nd  ed., Lippincott, p. 341.
Vascular Smooth Muscle and Sympathetic Nervous System Norepinephrine-activated alpha receptors cause calcium channels in vascular smooth muscle to open, which produces vasoconstriction In some vascular beds, beta-2 receptors promote vasodilation by decreasing calcium. C alcium  C auses  C ontraction in vascular smooth muscle Calcium channel blockers prevent vasoconstriction
Perfusion of Organs Tissue blood flow to a given organ is regulated on minute-to-minute basis in relation to tissue needs Neural mechanisms regulate CO and systemic vascular resistance (BP) to support local mechanisms Local control includes preferential vasoconstriction or vasodilation mediated by the SNS or by intrinsic mechanisms within the organ.
Tissue Factors Contributing to Local Control of Blood Flow Factors are released from an organ when it has too much or too little blood flow. Increase blood flow Histamine Decrease blood flow Serotonin
Endothelial Control of Vascular Smooth Muscle The endothelium produces factors that act on smooth muscle to produce vasoconstriction or vasodilation Vasodilating substances Nitric Oxide Vasoconstricting substances Angiotensin II, Prostaglandins, Endothelins
Functional Anatomy of the Heart Pericardium: Sac around heart Porth, 2007,  Essential of Pathophysiology,  2 nd  ed., Lippincott, p. 328. A “virtual space” which can become fluid or blood-filled (pericardial effusion).
Contraction: Actin & Myosin Binding http://www.sci.sdsu.edu/movies/actin_myosin_gif.html Spirito et al.,  NEJM  336, pg 775, 1997
Heart Valves Keep Blood Flow Unidirectional Semilunar valves: Control blood flow out of ventricles A ortic valve P ulmonic valve A-V valves : Control blood flow between atria & ventricles T ricuspid valve M itral valve Major function of heart valves:  Forward direction of blood flow Porth, 2007,  Essentials of Pathophysiology,  2 nd  ed., Lippincott, p. 329.
Cardiac Conduction System The conduction system stimulates the myocardium to contract & pump blood The conduction system controls the rhythm of the heart. Heart has two conduction systems One controls atrial activity  One that controls ventricular activity The two systems communicate when the impulse that causes atrial contraction travels to the ventricular system via the A-V node
SA Node Pacemaker of the heart Impulses originate here Located in posterior wall RA Fires at 60 -100 bpm Rate is determined by the autonomic nervous system (beta-1 receptors increase HR and muscarinic receptors decrease it). Porth, 2007,  Essentials of Pathophysiology,  2 nd  ed., Lippincott, p. 331.
AV Node Connects the atria & ventricles, provides one way conduction Speed of conduction is determined by the ANS Can assume pacemaker function if SA fails to discharge Fires at 40 -60 bpm Porth, 2007,  Essentials of Pathophysiology,  2 nd  ed., Lippincott, p. 331.
Purkinje Fibers Supply the ventricles Large fibers, rapid conduction for swift & efficient ejection of blood from heart Assume pacemaker of ventricles if AV fails Intrinsic rate is  15-40 bpm Porth, 2007,  Essentials of Pathophysiology,  2 nd  ed., Lippincott, p. 331.
ECG Electrical events recorded Electrical events precede mechanical events; know what they represent! P QRS T Porth, 2007,  Essentials of Pathophysiology,  2 nd  ed., Lippincott, p.331 & 333.
Cardiac Cycle Term used to describe the rhythmic pumping action of heart Cycle divided into 2 parts Systole : period during which ventricles are contracting Diastole : period during which ventricles are relaxed, filling with blood Simultaneous changes occur in pressure (LA,LV, aorta), ventricular volume, ECG, heart sounds during cardiac cycle
Porth, 2007,  Essential of Pathophysiology,  2 nd  ed., Lippincott, p. 334. The Wiggers diagram
Ventricular Systole Porth, 2007,  Essentials of Pathophysiology,  2 nd  ed., Lippincott, p. 334. Isovolumic (isometric) contraction Closure of AV valves (S1), all valves closed. No change in ventricular volume, ventricles contract.  When ventricular pressures > aortic & pulmonary pressures, semilunar valves open, leading to the -   Ejection period . Stroke volume ejected. Ventricles contract, then relax. Intraventricular pressures    and become less than pressures in aorta & pulm. artery. Blood from large arteries flows back toward ventricles and aortic/pulmonic valves shut (S2).
Ventricular Diastole Porth, 2007,  Essentials of Pathophysiology,  2 nd  ed., Lippincott, p. 334. Ventricular relaxation & filling. Isovolumic (isometric) relaxation: Semilunar valves closed,  ventricles relax.  No change in ventricular volume, but   ventricular pressure until it’s less than atrial pressures.  AV valves open, blood from atria enters ventricles -> Rapid filling period . Most ventricular filling in first third of diastole.(S3) During the last third, atria contract (atrial kick).
Atrial Contraction Last third of ventricular diastole Gives additional thrust to ventricular filling Important during tachycardia or when heart disease impairs ventricular filling May not be important in a person with a normal heart, especially at physiologic heart rates. Fourth heart sound (S4), when present, occurs when atria contract
Definitions Cardiac output (CO) Amount of blood the heart pumps/minute 3.5 - 8.0 L/minute Stroke volume (SV) Amount of blood the heart pumps each beat 70 ml/beat CO = SV x HR CO varies with body activities. CO varies by changes in SV and/or HR
Heart Rate Frequency with which blood is ejected from heart As HR     ->     CO HR is increased by activation of beta-1 receptors and decreased by activation of muscarinic receptors on the SA node. BUT as HR     ->     diastolic filling time    diastolic filling time  may     SV &    CO Tachycardia can be dangerous because the heart may not have time to fill adequately  ->      CO
Cardiac Output = Stroke Volume x Heart Rate  Preload Contractility Afterload
Stroke Volume Components Preload  Ventricular filling (volume) Afterload Resistance to ejection of blood from heart Contractility Pumping function of heart
Preload (“Volume”) Represents the volume of blood the heart must pump with each beat Largely determined by venous return and stretch of muscle fibers Venous return 64% of blood volume in veins Venous constriction mediated by alpha-1 receptors
Preload: Frank-Starling Law of the Heart Actin, myosin filaments that overlap and create cross bridge attachments leads to contraction of cardiac muscle Porth, 2007,  Essentials of Pathophysiology,  2 nd  ed., Lippincott, p. 336.
Implications of the Frank-Starling Law At normal volumes, as preload increases, stretch increases, which increases contractility. CO goes up both because of the increased volume and increased contractility The increase in contractility is independent of the SNS – it is an intrinsic property of the heart. At high volumes, the cardiac muscle is overstretched and contractility decreases. This is usually seen only in patients with heart failure (covered in CVII) who have fluid overload.
Afterload (“Resistance”) The amount of pressure the heart must develop during the period of isovolumic contraction to open the aortic and pulmonic valves. Arterial pressures are the major sources of resistance Right ventricle: pulmonary arterial pressure (low) Left ventricle:  systemic arterial pressure (high – equal to the diastolic BP in the absence of valve disease) Disease of the aortic or pulmonic valves      resistance Stenosis/narrowing of the valve This means that the heart has to develop an increased pressure to open the diseased valve. Diastolic hypertension also increases the pressure necessary to open the aortic valve.
Effect of Afterload on CO Guyton, 2006,  Textbook of Medical Physiology,  11th ed.,Saunders, p. 114.
Implications of the Afterload/CO Curve At normal afterloads, in people with normal hearts, afterload is not an important factor in cardiac output. Normally, preload is a much more important determinant of CO. The normal heart pumps what it gets from the venous system. In people with heart failure (CVII), afterload becomes an important determinant of CO.
Contractility Ability of the heart to change its force of contraction Strongly influenced by number of calcium ions that are available to participate in the contractile process. Determined by biochemical and biophysical properties that govern actin and myosin interactions in myocardial cells (Frank-Starling mechanism). Activation of beta-1 receptors in the ventricles by norepinephrine increases the availability of calcium ions and increases contractility.
Determinants of Blood Pressure BP = CO X Peripheral vascular resistance CO = SV X HR
Mechanisms of BP Regulation Arterial pressure must remain relatively constant as blood flow shifts from one area of body to another Method by which arterial pressure is regulated depends on whether short-term or long-term adaptation is needed
Mechanisms of BP Regulation Autonomic nervous system – short-term regulation RAAS (Renin-angiotensin-aldosterone system) – longer term regulation Kidneys – control blood volume as well as the RAAS – a long-term mechanism of blood pressure control.
The Baroreceptor Reflex Baroreceptors in the aortic arch and carotid artery Autonomic centers in the brainstem Cardiac muscle, cardiac conduction system, and vascular smooth muscle.
The Sensory Components of the Baroreceptor Reflex – Chemo and Stretch Receptors Porth, 2007,  Essentials of Pathophysiology,  2 nd  ed., Lippincott, p. 364.
ANS Regulation of BP – the Baroreceptor Reflex   Be sure you know which receptors are where!!! McCance & Heuther, 2002,  Pathophysiology:  The Biologic Basis for Disease in Adults & Children, Mosby,  p.961
Neurotransmitters Porth,  Pathophysiology, Concepts of Altered Health States, 7 th  ed.,  2005, Lippincott, p. 1151.
Long-term Regulation of BP Primarily controlled by kidneys Neural mechanisms act rapidly, but can’t maintain their effectiveness over time Kidneys’ control in long term is thru regulation of Na +  and H 2 0 balance RAAS  Vasopressin
Humoral Mechanisms: Renin-angiotensin-aldosterone system Porth, 2007,  Essentials of Pathophysiology,  2 nd  ed., Lippincott, p. 365. MUST KNOW THIS!
Vasopressin (Antidiuretic Hormone (ADH)) Porth,  Pathophysiology, Concepts of Altered Health States, 7 th  ed.,  2005, Lippincott, p. 756.
Porth,  Pathophysiology, Concepts of Altered Health States, 7 th  ed.,  2005, Lippincott, p. 756. The ANS and RAAS systems work in concert.
Which of the following is an  important  determinant of cardiac output in a normal person? Afterload. Heart rate. Venous return (preload) Total peripheral resistance.
You assess a patient’s pulse to be 40 bpm. He is not an athlete. Given this HR, the electrical impulses in the heart are probably originating from: SA Node AV Node An ectopic atrial focus Purkinje Fibers
Angiotensin II causes: Release of aldosterone Vasoconstriction of arterioles Increased arterial blood pressure All of the above
Disorders of  Blood Pressure Regulation:  Hypertension and  Orthostatic Hypotension
Orthostatic Hypotension Abnormal drop in BP on assumption of the standing position Defined as a drop in systolic pressure > 20 mm Hg or drop in diastolic pressure > 10 mm Hg when going from lying to standing In absence of normal circulatory reflexes and/or if blood volume is decreased, blood pools in lower part of the body when the standing position is assumed (decreased venous return), CO    and blood flow to the brain is inadequate   dizziness, syncope (fainting), or both
Porth, 2007,  Essentials of Pathophysiology,  2 nd  ed., Lippincott, p. 374 Orthostatic Hypotension
Causes Reduced blood volume (dehydration) (reduced preload) This is the most common cause of dizziness and fainting, especially in young, health people. Drug-induced orthostatic hypotension Impairment of venous return (reduced preload) (Ca 2+  channel blockers) Impairment of the baroreceptor reflex (beta blockers, alpha-1 blockers) Diuretics (reduced preload) Aging – sluggish reflexes, including the baroreceptor reflex Bedrest – deconditioning  Disorders of the autonomic nervous system
Treatment Alleviating cause Rehydrate, change meds Help cope with disorder, prevent falls, injury Gradual ambulation (sit on edge of bed, move legs) Avoid venodilation (drinking ETOH; exercise in warm environment) Maintain hydration
Hypertension Common health problem in adults A leading risk factor for cardiovascular disorders (myocardial infarction, heart failure, stroke, vascular disease) More common in young men than young women, blacks compared with whites, in persons from lower socioeconomic groups, and with increasing age Diabetics are more likely to have hypertension and it is more likely to lead to cardiovascular disease than in nondiabetics.
Hypertension PRIMARY “ Essential hypertension” Chronic elevation of BP occurs without evidence of other disease 90-95% of hypertension SECONDARY Elevation of BP occurs from some other disorder Kidney disease Chronic renal failure disorders of adrenocorticoid hormones (pheochromocytoma)
Hypertension Definitions JNC-VII *  (June 2003) “ Prehypertension” (120-139/80-89) Stage I (140-159/90-99) Stage II (160-179/100-109) Stage III (>180/>110) * 7th Report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure
Constitutional Risk Factors Family history Hereditary pattern unclear, genes not identified Age related changes BP higher with advancing age Insulin resistance, metabolic syndrome, diabetes (especially type II) Race African Americans more prevalent, early onset, more severe; greater renal, CV damage Less known about other races
Lifestyle Risk Factors Diet high in Na +  & saturated fats  Obesity  Physical inactivity  Excessive alcohol consumption Oral contraceptives in predisposed women
Consequences of HTN Usually related to long term effects of HTN on other organs, “ target organ damage ”. HTN seems to accelerate atherosclerotic vascular disease (covered later today) Heart Left ventricular hypertrophy, coronary artery disease (angina, myocardial infarction), heart failure Brain Stroke or transient ischemic attack Chronic kidney disease Peripheral vascular disease Retinopathy
Consequences of HTN Heart: LV Hypertrophy    workload of LV (   afterload); LV tries to compensate for    workload. LV hypertrophy is major risk factor for ischemic heart disease, dysrhythmias, heart failure, sudden death
Consequences of HTN Vascular damage Coronary arteries – myocardial infarction (CVII) Peripheral blood vessels – peripheral vascular disease Kidney – renal failure Cerebral blood vessels – stroke
Diagnosis of Hypertension Repeated BP measurements Average of > 2 readings taken at > 2 visits after an initial screening visit; over several months Laboratory tests, x-rays looking for target organ damage ECG, Urinalysis, Hb, Hct, Na + , K + , Cr, glucose, triglycerides, cholesterol
Treatment of Hypertension Lifestyle modification is the first line of treatment Weight reduction, regular physical exercise, DASH eating plan, reduction of dietary sodium intake, moderation of alcohol intake Pharmacologic treatment Goal: To achieve and maintain systolic BP below 140 mm Hg and diastolic BP below 90 mm Hg
Lehne, 2009,  Pharmacology for Nursing Care, 6 7h  ed., Elsevier, p. 500 Sites of Action
Pharmacologic Treatment Diuretics Sympatholytics Beta-adrenergic blockers Alpha-1 adrenergic blockers Centrally-acting alpha-2 agonists Drugs that block norepinephrine release Act on RAAS Renin inhibitor ACE inhibitors Angiotensin II receptor blockers Aldosterone antagonists Others Ca +2  channel blockers Direct-acting vasodilators Adapted from Lehne, 2009,  Pharmacology for Nursing Care, 7 th  ed., Elsevier, Table 46-5, p. 502
Pharmacologic Treatment Compliance is a  huge  issue Lifetime treatment Many of the drugs have unpleasant side effects Many are expensive
Algorithm for Treating Hypertension Lifestyle modifications Goal BP not met Stage 1 – thiazide diuretic /consider ACEI,ARB, beta blocker, CCB or combination Stage 2 – 2-drug combo (usually a thiazide + ACEI, ARB, beta blocker or CCB Goal BP not met Optimize dosage or add a drug from a different class Continue adding drugs from other classes until goal is achieved Goal BP not met Adapted from Lehne, 2009,  Pharmacology for Nursing Care, 7 th  ed., Elsevier, p. 507
Classes of Antihypertensive Drugs Recommended for Initial Therapy in Patients with High-Risk Comorbid Conditions Adapted from Lehne, 2009,  Pharmacology for Nursing Care, 7 th  ed., Elsevier, p. 508 Condition Drug Classes Recommended for Initial Therapy of HTN Diuretic Beta Blocker ACEI ARB CCB Aldosterone Antagonist Heart Failure X X X X X Post MI X X X Coronary Artery Disease Risk X X X X Diabetes X X X X X Chronic Kidney Disease X X Recurrent Stroke Prevention X X
Drugs That Affect BP: Diuretics Lehne, 2009,  Pharmacology for Nursing Care, 7 th  ed., Elsevier, p. 500
Classification of Diuretics Thiazide diuretics – Hydrochlorothiazide (HCTZ ® ) & chlorthalidone High-ceiling (loop)– Furosemide (Lasix ® ) K +  sparing: Non-aldosterone antagonists - Triamterene (Dyrenium ® ) Aldosterone receptor antagonists – Spironolactone (Aldactone) Osmotic diuretics – Mannitol All diuretics  indirectly  prevent the re-absorption of water in the kidneys!
Thiazides Lehne, 2009,  Pharmacology for Nursing Care, 7 th  ed., Elsevier, p. 445 Prevent re-absorption of  sodium  in the distal tubule.
Thiazides: hydrochlorthiazide & chlorthalidone Uses: Essential hypertension Often first drug used May be part of multiple-drug therapy Edema Preferred drugs for mobilizing edema associated with mild, moderate heart failure
Thiazide Diuretics Adverse Effects Hypokalemia Hyponatremia, hypochloremia, dehydration Orthostatic hypotension Avoid in pregnancy if possible May reduce placental perfusion (not for routine use in pregnancy) Nocturia if taken at night Drug Interactions Digoxin -> digoxin toxicity (ALL K + -LOSING DIURETICS) Lithium -> lithium toxicity  (ALL DIURETICS!!!) NSAIDS ->  Reduced natriuresis/diuresis
Loop Diuretics Lehne, 2009,  Pharmacology for Nursing Care, 7 th  ed., Elsevier, p. 445 Prevent the re-absorption of  sodium  from the ascending Loop of Henle.
Furosemide (Lasix ®) A second-line diuretic for hypertension but has many other uses. Used for pulmonary edema associated with congestive heart failure Edema of hepatic, cardiac, or renal origin unresponsive to less efficacious diuretics Promotes diuresis in renal impairment
Loop Diuretics: Adverse Effects Hypokalemia Hyponatremia, hypochloremia, dehydration Orthostatic hypotension Ototoxicity Avoid in pregnancy if possible Nocturia if taken at night
Loop Diuretics: Drug Interactions Digoxin – hypokalemia is dangerous with digoxin Nitrates/other antihypertensives – increased hypotensive effects Other ototoxic drugs (aminoglycoside antibiotics) Lithium – lithium toxicity NSAIDS can attenuate the diuretic effect of furosemide
Potassium-Sparing Diuretics Lehne, 2009,  Pharmacology for Nursing Care, 7 th  ed., Elsevier, p. 445 Prevent the re-absorption of  sodium  from the collecting tubule and duct.
Spironolactone - Aldactone ®   Hypertension Edema Commonly used in combination with thiazide or loop diuretics Effects are delayed
Spironolactone (Aldactone ®) Adverse effects Hyperkalemia Avoid use of potassium supplements Synergistic with ACE inhibitors and ARBs Endocrine effects Spironolactone has a steroid structure and can cause a variety of effects similar to steroid hormones, such as gynecomastia and impotence in men, menstrual irregularities, hirsutism, and deepening of the voice in women
Spironolactone (Aldactone ®) Drug interactions Potassium supplements and salt substitutes are contraindicated ACE inhibitors or ARBs may exacerbate the tendency to hyperkalemia Pregnancy category D because of steroid-like effects on the fetus
Triamterene Often given in combination with a thiazide Dyazide = hydrochlorothiazide + triamterene Adverse Effect Hyperkalemia – AVOID K +  supplements Drug Interactions ACE Inhibitors/ARBs:  Hyperkalemia potential NSAIDS may blunt diuretic effect and indomethacin may precipitate renal failure Take after meals in AM Avoid potassium rich diet items -- bananas, orange juice,  salt substitutes  (which are likely to be KCl)
Osmotic Diuretics -Mannitol Lehne, 2009,  Pharmacology for Nursing Care, 7 th  ed., Elsevier, p. 445 Prevents re-absorption of  water  from the proximal tubule.
Mannitol Must be given parenterally Therapeutic uses Prophylaxis of renal failure Reduction of intracranial pressure Increased intra-ocular pressure When mannitol is in the bloodstream, before it gets into the renal tubules, it increases the osmotic pressure of the blood and draws edema fluid into the vascular system. Mannitol is filtered into the glomerulus, drawing the excess water with it and holding it in the renal tubules for excretion.
Osmotic Diuretics Adverse Effects Edema (caused by mannitol leaving the circulation and drawing water into the tissues with it) Administer with extreme caution in heart failure because of its ability to increase vascular volume and overload the heart. Dehydration  Orthostatic hypotension Drug Interactions Mannitol is not metabolized, very inert. It has no significant drug interactions
Drugs Acting on RAAS Lehne, 2009,  Pharmacology for Nursing Care, 7 th  ed., Elsevier, p. 500 Renin inhibitor
Renin inhibition
Renin Inhibitor Renin inhibition should prevent all activation of the renin-angiotensin aldosterone system. Only one such drug, aliskiren (Tekturna), is approved for use as monotherapy or in combination with hydrochlorothiazide. Like other drugs that target the RAAS, aliskiren is pregnancy category D because of evidence of fetal harm.
Porth, 2007,  Essential of Pathophysiology,  2 nd  ed., Lippincott, p. 365. ACE Inhibitors (ACEI) Captopril, lisinopril, enalapril, and others
Lehne, 2009,  Pharmacology for Nursing Care, 7 th  ed., Elsevier, p. 469
Therapeutic Uses of ACEI Hypertension Heart failure Protective effects in diabetic nephropathy Post MI prophylaxis Prevention of MI, stroke, and death in patients at risk
Therapeutic Uses of ACEIs: HTN Initial responses: reduced formation of angiotensin II Prolonged therapy: additional reduction in BP Do not interfere with cardiovascular reflexes Do not cause hypokalemia but may contribute to the tendency to  hyperkalemia  if given with potassium-sparing diuretics. Do not induce lethargy, weakness, sexual dysfunction as other antihypertensives may. REDUCE THE RISK OF CV MORTALITY CAUSED BY HEART FAILURE REDUCE THE RISK OF RENAL FAILURE IN DIABETICS
ACE Inhibitors: Adverse Effects Bilateral renal artery stenosis is a contraindication because these drugs can precipitate acute renal failure in these patients Dry cough – an effect of increased bradykinin First dose hypotension – Most prominent in patients with very high BP or those on diuretics. Teratogenic –  contraindicated in pregnancy Angioedema – due to increased bradykinin, may be very serious
Westra S and de Jager C. N Engl J Med 2006;355:295 A 75-year-old man presented to the emergency department with diffuse swelling of his tongue that had begun a few hours earlier.  He had been taking 25 mg of captopril twice daily for the past 3 years because of hypertension.  He was treated with epinephrine, corticosteroids, and antihistamines and the swelling resolved over a three-hour period.  The angioedema was likely due to the angiotensin-converting enzyme inhibitor.
ACE Inhibitors: Drug Interactions Digoxin    Increased digoxin levels Lithium    Increased lithium levels/toxicity K +  sparing diuretics     hyperkalemia Potassium supplements     hyperkalemia
ACE Inhibitors Can be combined with a thiazide diuretic All are oral except for enalaprilat, which is IV only Patients with renal impairment may need dosage reduction
Porth, 2007,  Essential of Pathophysiology,  2 nd  ed., Lippincott, p. 365. Angiotensin II Receptor Blockers (ARBs) Losartan, valsartan, candesartan, and others
ARB Therapeutic Uses Hypertension Reductions in BP = ACEI Heart failure – prevent the progression and improve outcomes Diabetic nephropathy – prevents progression Post-MI prophylaxis Stroke prevention
ARBs Adverse effects Well tolerated Do not cause cough Angioedema Fetal harm –  contraindicated in pregnancy Renal failure Drug interactions Hypotensive effects are additive with other anti-HTN drugs Do not cause hyperkalemia but may contribute if given with potassium-sparing diuretics
Porth, 2007,  Essential of Pathophysiology,  2 nd  ed., Lippincott, p. 365. Aldosterone  Antagonists Spironolactone Eplerenone (Inspra) Potassium-sparing diuretics (covered previously as diuretics) Promote Na +  & H 2 0 excretion in the collecting tubule & duct
Drugs That Affect BP:  Sympatholytics (Antiadrenergics) Beta blockers Alpha-1 blockers Alpha/beta blockers Centrally acting alpha-2 agonists Adrenergic neuron blockers (inhibit synthesis or release of norepinephrine) Ganglionic blockers (not used, we will not cover)
Drugs That Affect BP:  Sympatholytics (Antiadrenergics) Lehne, 2009,  Pharmacology for Nursing Care, 7 th  ed., Elsevier, p. 500 Sites of Action
Beta-Adrenergic Blockers* Widely used anti-hypertensive drugs Actions in hypertension Blockade of cardiac beta-1 receptors ->↓ HR, contractility  ->   ↓ CO Suppress reflex tachycardia caused by vasodilators Blockade of beta-1 receptors in JG cells in kidney  ->   ↓  renin release  ->   ↓  RAAS mediated vasoconstriction (angiotensin II) and volume expansion (aldosterone) Long-term use       peripheral vascular resistance *Recall from Dr McPherson’s lecture; Lehne Chapter 18
Beta-Adrenergic Blockers Some block both beta-1 and beta-2 receptors (nonselective) Some have greater affinity for beta-1 than beta-2 (“cardioselective”) – but the selectivity is not absolute Some are partial agonists – they are said to have “intrinsic sympathomimetic activity” or ISA
Clinical Pharmacology of Some Beta Blockers Adapted from Lehne, 2009,  Pharmacology for Nursing Care, 7 th  ed., Elsevier, p. 167 Generic/trade name ISA Cardioselective (beta 1  > beta 2 ) Acebutolol/Sectal ® + Atenolol/Tenormin ® 0 Esmolol/Brevibloc ® 0 Metolprolol/Lopressor ® Slow release/Toprol XL 0 Nonselective (beta 1  = beta 2 ) Pindolol/Visken ® +++ Propranolol/Inderal ® Slow release/Inderal LA® 0 Nonselective alpha/beta blockers Carvedilol/Coreg ® 0 Labetolol/Normodyne ®  or Trandate ® 0
Therapeutic Uses Adapted from Lehne, 2009,  Pharmacology for Nursing Care, 7 th  ed., Elsevier, p.168 A – approved; I - investigational Drug HTN Angina Dysrrhy-thmias MI Migraine Stage Fright Heart Failure Cardioselective Acebutolol A I A Atenolol A A I A I I Esmolol I A Metolprolol A A I A I A Nonselective Pindolol A I I Propranolol A A A A A I Nonselective alpha/beta blockers Carvedilol A I A A Labetolol A
Sympatholytics - Alpha-1 antagonists Sites of Action Lehne, 2009,  Pharmacology for Nursing Care, 7 th  ed., Elsevier, p. 500
Alpha-1 Antagonists* Doxazosin, terazosin, prazosin and others Block alpha-1 receptors on arterioles and veins    prevent SNS-mediated vasoconstriction    vasodilation       peripheral resistance,    venous return to heart Not used as first line therapy for hypertension Orthostatic hypotension is a big problem Sexual side effects are big reasons for noncompliance Doxazosin, terazosin and tamsulosin (Flomax) used for BPH. *Recall Dr McPherson’s lecture; Lehne Chapter 18
Centrally Acting Alpha-2 Agonists Sites of Action Lehne, 2009,  Pharmacology for Nursing Care, 7 th  ed., Elsevier, p. 500
Centrally Acting Alpha-2 Agonists Clonidine, methyldopa (agent of choice for chronic hypertension in pregnancy – not for pre-eclampsia) Act within brainstem (alpha-2 receptors) to suppress sympathetic outflow to the heart and blood vessels  ->  vasodilation,    CO      BP Cause dry mouth, sedation, hemolytic anemia, liver disorders Rebound hypertension if abruptly stopped
Calcium Channel Blockers Dihydropyridines Nifedipine Amlodipine (Norvasc) Promote dilation of arterioles, little effect on veins Non-dihydropyridines Verapamil, diltiazem Promote dilation of arterioles, little effect on veins Also act on heart to slow conduction and decrease contractility
Lehne, 2009,  Pharmacology for Nursing Care, 7 th  ed., Elsevier, p. 481 Calcium Channels in the Heart
Verapamil Blocks Ca +2  channels in arterioles, heart Dilation of peripheral vessels      BP Dilation of coronary arteries       coronary perfusion Blockade at SA node       HR Blockade at AV node       nodal conduction Blockade in myocardium       contractile force Indications Angina pectoris, hypertension, dysrhythmias
Verapamil: Adverse Effects Constipation (why?) Dizziness, facial flushing, headache, edema of ankles, feet (why?) Bradycardia, conduction defects (why?)
Nifedipine and amlodipine (dihydropyridines) Block Ca +2  channels in arterioles Dilation of peripheral vessels  ->    BP Dilation of coronary arteries  ->     coronary perfusion Do NOT block  cardiac  Ca +2  channels at therapeutic doses
Nifedipine & Amlodipine:Indirect (reflex) Effects Lowering BP    baroreceptor reflex  ->     firing of SNS to beta receptors in the heart  But, nifedipine lacks direct cardiosuppressant actions, cardiac stimulation is unopposed  ->    HR,    contractility Net effect is the sum of the direct effect (vasodilation) and the indirect effect (reflex cardiac stimulation)
Nifedipine & amlodipine: Uses Angina pectoris Vasospastic angina, angina of effort Hypertension Essential hypertension Nifedipine – only use sustained-release formulation for hypertension Take whole, do not crush or chew Amlodipine has a longer half-life than nifedipine and does not have a sustained-release formulation
Nifedipine & Amlodipine: Adverse Effects Flushing, dizziness, headache, edema  Gingival hyperplasia Constipation Do not exacerbate conduction abnormalities Do cause reflex tachycardia  ->     cardiac oxygen demand  ->  angina  Give with a beta blocker to counteract this in patients with angina
Nifedipine blocks Ca +2  channels in arterioles. This results in: Vasoconstriction of peripheral vessels Vasoconstriction of coronary arteries Decrease in HR Dilation of peripheral vessels
Hypertensive Emergencies (SBP >200 mm Hg or DBP >120 mm Hg) Symptoms of actual or impending end-organ damage Neurological  Hypertensive encephalopathy  Cerebral vascular accident/cerebral infarction  Subarachnoid hemorrhage  Intracranial hemorrhage Cardiovascular  Myocardial ischemia/infarction  Acute left ventricular dysfunction  Acute pulmonary edema  Aortic dissection Other  Acute renal failure/insufficiency  Retinopathy  Eclampsia  Microangiopathic hemolytic anemia
Sodium nitroprusside-Nitropress ® A very powerful arterial vasodilator No reflex tachycardia Overshoot hypotension is possible but can be correctly quickly by stopping or slowing the infusion Titrate to blood pressure An infusion pump is essential. An arterial line or an automatic blood pressure cuff must be used to check BP continuously.
Adverse Effects Cyanide poisoning Likely in pts with liver disease Avoid prolonged rapid infusion Thiocyanate Toxicity Likely when drug given over days CNS effects (disorientation, delirium) Avoid infusions > 3 days; monitor plasma thiocyanate Lehne, 2009,  Pharmacology for Nursing Care, 7 th  ed., Elsevier, p. 492
IV Calcium Channel Blockers Fenoldepam – long half-life Nicardipine – long half life Clevidipine – short half-life, easy to titrate Titrate similarly to sodium nitroprusside All can cause reflex tachycardia and hypotension.
How do diuretics decrease blood pressure? Block beta adrenergic receptors Inhibit angiotensin converting enzyme Act on renal tubules to promote water excretion Act as a vasodilator
Disorders of Arterial Circulation Hyperlipidemia Leading to Atherosclerosis
Hyperlipidemia Triglycerides, phospholipids, cholesterol classified as lipids; chemical substances insoluble in water but soluble in alcohol. Three types of biological lipids Triglycerides Used as sources for energy metabolism Phospholipids Structural components of lipoproteins, clotting components, myelin sheath, cell membranes Cholesterol Basis of steroid hormones and an important cell membrane component
Lipoproteins Lipids (cholesterol, triglycerides) insoluble in plasma Encapsulated in lipid transport particles (lipoproteins) composed of phospholipids and embedded proteins Apoproteins are large proteins contained within the phospholipid coat of the lipoprotein Porth, 2007,  Essentials of Pathophysiology,  2 nd  ed., Lippincott, p. 348.
Five Types of Lipoproteins Porth, 2007,  Essentials of Pathophysiology,  2 nd  ed., Lippincott, p. 348. -Of the five, LDLs and HDLs are the most important - As the density of the lipoprotein increases, the proportion of triglycerides decreases and the proportion of cholesterol increases
Lipoprotein Synthesis & Transport Porth, 2007,  Essentials of Pathophysiology,  2 nd  ed., Lippincott, p. 349. Synthesis in small intestine, liver Liver important in LDL metabolism; removes LDL via LDL receptors
HDL “ Good cholesterol” Carries cholesterol FROM tissues TO liver High HDL prevents atherosclerosis HDLs are scavengers, picking up cholesterol from  deposits in the arteries and bringing it back to the liver for disposal HDL inhibits uptake of LDLs into cells Exercise, moderate ETOH    HDLs Smoking, diabetes or metabolic syndrome (sort of a diabetic prodrome)   HDLs
LDL Familial defects in LDL receptor – “familial hypercholesterolemia” Inadequate, or defective hepatic uptake of LDL    circulating LDL “ Receptor disease”
LDL Receptors in Liver Remove LDLs from the Blood  Robbins & Cotran  Pathologic Basis of Disease  (7th ed), 2005, Elsevier, p.158
Hypercholesterolemia Primary Develops independent of other causes; defective synthesis of apoproteins, lack of receptors, defective receptors, defects in handling of cholesterol in cell that are genetically determined Secondary Associated with other health problems & behaviors (high fat diet, obesity, diabetes mellitus) Porth, 2007,  Essentials of Pathophysiology,  2 nd  ed., Lippincott, p. 350. Xanthomas (deposits of cholesterol) develop in certain areas, including the knuckles.
Diagnosis, Screening All adults 20 years of age and older should have a fasting lipoprotein profile done every 5 years Total cholesterol, LDL, HDL, TG See Porth, text on page 350-351 for specific recommendations Also Table 49.4 in Lehne
Classification of LDL, Total, and HDL Cholesterol Cholesterol Level (mg/dL) Classification Total <200 Optimal 200-239 Borderline high > 240 High LDL cholesterol <100 Optimal 100-129 Above optimal 130-159 Borderline high 160-189 High > 190 Very high Adapted from Porth, 2007,  Essentials of Pathophysiology,  2 nd  ed., Lippincott, p. 350. Cholesterol Level (mg/dL) Classification HDL cholesterol <40 Low > 60 High
Why are increased blood lipids so bad? Increased blood lipids, particularly cholesterol, increase the risk of a vascular disease called atherosclerosis. Fatty deposits form in arterial walls This increases the risk of clot formation and occlusion of an artery. Occluded arteries cause myocardial infarctions, stroke, and peripheral vascular disease. Atherosclerosis leads to arteriosclerosis (hardening of the arteries) which increases the risk of aneurysms and other vessel wall problems.
Atherosclerosis Atheros (glue/paste) Sclerosis (hardening) Formation of fibrofatty lesions (atheromas) in the intimal lining of large and medium sized arteries (aorta, coronaries, carotids, and many others)
Atherosclerotic Lesions Fatty streak Thin, flat, yellow discolorations that progressively enlarge by becoming thicker and more elevated.  Present in children. Precursors to atheromata? Fibrous atheromatous plaque Complicated lesions
Atheromatous Plaque Porth, 2007,  Essential of Pathophysiology,  2 nd  ed., Lippincott, p. 353 Plaque Complicated Lesion
Definitions Thrombus = clot Embolus = a clot that breaks off from its initial location and travels through the vascular system. Stenosis = narrowing or closing off of a vessel (or a heart valve). Mural = wall (a mural thrombus is a clot in the wall of a vessel or a chamber of the heart)
Robbins & Cotran  Pathologic Basis of Disease  (7th ed), Elsevier, 2005, p.517
Porth, 2007,  Essentials of Pathophysiology,  2 nd  ed., Lippincott, p. 352. Atheromas tend to develop at sites of turbulent flow – near branch points As the artheroma develops, it creates more of a constriction, which produces more turbulent flow. See Figure 17.8 in Porth!
Laminar & Turbulent Flow Porth, 2007,  Essentials of Pathophysiology,  2 nd  ed., Lippincott, p. 323.
Risk Factors for Atherosclerosis Age Men > 45 y.o.; women > 55 y.o. (or premature menopause) Family History MI before 55 y.o. in father or before 65 y.o. mother Current cigarette smoking Hypertension (BP > 140/90) Hyperlipidemia Low HDL (< 40 mg/dL) High LDL Diabetes mellitus
Risk Factors C-reactive protein (CRP) Marker of inflammation; better than LDL? Homocysteine Inhibits coagulation, causes endothelial damage, important in initial phases? Serum lipoprotein (a) Part of the LDL; promotes foam cells Infectious agents Chlamydia pneumoniae
Clinical Manifestations of Vascular Disease Cotran (1999) pg. 499
Management Reduction in LDL is primary target for cholesterol-lowering therapy, particularly for people at risk for CHD* Age, family history of premature CHD, cigarette smoker, hypertension, low HDL, diabetes mellitus Some evidence that when lipids are lowered, at least with statin drugs, that atheromatous changes regress. *See Porth, Table 17-1, page 351 and Lehne, Table 49-4, p. 551
Management Dietary changes*    calories,    saturated fats,    cholesterol Lifestyle changes    physical activity, smoking cessation, weight loss Pharmacologic treatment * See Lehne, Table 49-6, pg. 556
Lipid-Lowering Drugs Porth, 2007,  Essentials of Pathophysiology,  2 nd  ed., Lippincott, p. 349. Mechanisms: Affect cholesterol production by liver Remove cholesterol from bloodstream  LDL receptors  Cholesterol absorption from intestine    intravascular conversion of VLDL and IDL to LDL
Classes of Drugs Used in Treatment of Hypercholesterolemia HMG-CoA reductase inhibitors (statins) Bile acid-binding resins Cholesterol absorption inhibitor agents Niacin and its congeners Fibric acid derivatives
Statins Atorvastatin [Lipitor] Fluvastatin [Lescol] Lovastatin [Mevacor] Provastatin [Pravachol] Rosuvastatin [Crestor] Simvastatin [Zocor]
Statins Beneficial Actions: Reduce cholesterol synthesis in liver    LDL receptors (most important)    LDLs    HDLs    TG Timing: Results within 2 weeks; maximal 4-6 weeks If drug is stopped, serum cholesterol returns to pretreatment levels (lifelong treatment)
Statins   LDL Receptors in Liver ->    LDLs  Robbins & Cotran  Pathologic Basis of Disease  (7th ed), 2005, Elsevier, p.158
Statins Cardiovascular actions Reduce inflammation at plaque sites Improve endothelial cell function Enhance blood vessel dilation Reduce risk of thrombosis Increased bone formation Enhance osteoblast activity       risk of osteoporosis, fractures
Statins: Therapeutic Uses Hypercholesterolemia Prevention of cardiovascular events MI, stroke, angina Diabetes ADA: Pts > 40 y.o. with total cholesterol > 135 mg/dL- regardless of LDL ACP: All pts with type 2 diabetes with coronary artery disease, even if they don’t have high cholesterol; all adults with type 2 diabetes plus one CV risk factor - even if they don’t have high cholesterol
Statins: Side Effects Myopathy/rhabdomyolysis Report unexplained muscle weakness, tenderness Rosuvastatin higher risk Hepatotoxicity Monitor liver enzymes every 6-12 months Avoid use for pts with viral, alcoholic hepatitis
Statins: Drug Interactions Fibrates and ezetimibe Also    cholesterol, so their activity might be additive to statins Can also cause myopathy, so the danger from that would also be increased Inhibitors of cytochrome P450 like ketoconazole, erythromycin, HIV protease inhibitors, etc., inhibit the metabolism of statins and raise blood levels       risk of adverse effect
Bile Acid Sequestrants Cholestyramine, colestipol, and colesevelam Biologically inert, insoluble in water, cannot be absorbed from GI tract, simply pass through intestine, excreted in feces Absorb bile acids in the intestine and keep them from being reabsorbed into the bloodstream. New bile acids must be synthesized, which requires cholesterol. LDLs are internalized into liver cells as a source of cholesterol. This lowers LDLs. Reduce LDL cholesterol Maximal reduction within one month (20%) LDL levels return to pre-treatment levels when drug is discontinued
Bile Acid Sequestrants Porth, 2007,  Essentials of Pathophysiology,  2 nd  ed., Lippincott, p. 349. Prevent the absorption of cholesterol in the intestine
   Bile acid reabsorption (GI)    synthesis in liver       need for cholesterol      LDL receptors  Robbins & Cotran  Pathologic Basis of Disease  (7th ed), 2005, Elsevier, p.158
Therapeutic Use Reduce LDL cholesterol Drug plus diet ->    LDL by 15-30% Usually combined with statin    LDL by 50%
Adverse effects Devoid of systemic effects GI symptoms (except colesevelam) Constipation Bloating Indigestion Nausea
Bile Acid Sequestrants  Drug Interactions Decreased absorption of: Warfarin -Acetaminophen Thiazides -Beta blockers Digoxin -Corticosteroids Iron -Thyroid hormones Fat-soluble vitamins A, D, E, and K (except colesevelam) Take oral medications 1 hour before or 4 hours after the bile acid sequestrant.
Cholesterol Absorption Inhibitors Ezetimibe (Zetia ® )
Ezetimibe (Zetia ® ) Mechanism of action Acts on cells in the brush border of the intestine and inhibits cholesterol absorption Blocks absorption of dietary cholesterol and cholesterol secreted in bile Lowers total cholesterol, LDLs, TG and raises HDLs Used as adjunct to diet modification Can be used as monotherapy or with a statin Recent evidence that the combo of ezetimibe and simvastin (Vytorin) actually worsened plaques rather than making them better .
Ezetimibe (Zetia):  Drug Interactions Statins -    risk of liver damage Fibrates – both    the concentration of cholesterol in the bile       the risk of gallstones Bile-acid sequestrants- impair the absorption of ezetimibe Cyclosporine- inhibits metabolism of ezetimibe       its concentration.
Nicotinic Acid (Niacin) [Niacor, Niaspan] Porth, 2007,  Essentials of Pathophysiology,  2 nd  ed., Lippincott, p. 349. Decreases production of VLDLs by inhibiting lipolysis in adipose tissue       LDL
Nicotinic acid (Niacin) Effect on plasma lipoproteins: Reduces triglycerides (20 – 50%) and LDLs (5-25%) Raises HDLs (15-35%) Drug of choice to lower triglyceride levels in patients at risk for pancreatitis. More effective when combined with statin Triple therapy (nicotinic acid, statin, bile-acid sequestrant)     LDL 70% Nicotinic acid is also a B-vitamin, but doses as a vitamin are much smaller than as a lipid-lowering drug.
Nicotinic Acid: Adverse Effects Intense flushing of the head & neck in nearly all pts– diminishes in several weeks, attenuated with aspirin GI upset – take with food Hepatotoxic – follow liver enzymes Raises blood levels of homocyteine, a substance thought to increase cardiovascular risk.  To counteract this, add folic acid supplements. Hyperglycemia – use with caution in diabetics
Fibric Acid Derivatives (Fibrates) Porth, 2007,  Essentials of Pathophysiology,  2 nd  ed., Lippincott, p. 349. Gemfibrozil [Lopid] Fenofibrate [Tricor] Increase lipoprotein lipase  ->     VLDLs and    TG storage in adipose tissue (   serum TG) Also    HDL No effect on LDL
Fibric acid derivatives Adverse effects Gallstones – Increase biliary cholesterol saturation  ->  increase risk of gallstones Myopathy – like the statins, can cause myopathy Heptatotoxicity – like the statins, fibric acid derivatives are hepatotoxic; Monitor liver enzymes Because of overlapping adverse effects, the combo of a statin and a fibric acid derivative should be used with great caution. Pregnancy category C
Fibric acid derivatives Drug interactions Warfarin – Gemfibrozil increases the efficacy of warfarin by displacing it from protein binding sites. Follow INR closely Use with caution in statins because of the increase in risk of myopathy
Which of the following drugs are insoluble in water, cannot be absorbed from the GI tract and pass through the intestine? Bile acid sequestrants HMG Co-A reductase inhibitors Fibric acid derivatives Nicotinic acid
Which of the following drug classes has been shown to  reverse  athrosclerotic changes? Statins Fibric acid derivatives Bile acid sequestrants Niacin
Questions?

Cvi fall 2011

  • 1.
    Control of CardiovascularFunction, Disorders of Blood Flow & Blood Pressure, Hyperlipidemia & Artherosclerosis
  • 2.
    Review of HemodynamicsBlood vessel structure, function Regulation of cardiac output Mechanisms of blood pressure regulation Disorders of blood pressure Hypertension Orthostatic hypotension Drugs that affect blood pressure Disorders of arterial circulation Hyperlipidemia, atherosclerorosis Drugs that lower LDL cholesterol
  • 3.
    Pulmonary and Systemic Circulation Baxter Corp. (1999)
  • 4.
    Differences in theTwo Systems PULMONARY Low pressure system (MPAP 12 mmHg) Good for gas exchange SYSTEMIC High pressure system (MAP 90-100 mmHg) Good for distant transport, against gravity
  • 5.
    How does bloodget back to the heart? Lehne, 2009, Pharmacology for Nursing Care, 7 th ed., Elsevier, p 461
  • 6.
    Principles of BloodFlow Hemodynamics Heart is an intermittent pump, blood flow is pulsatile Factors governing the function of the CV system Volume Pressure Resistance Flow
  • 7.
    Determinants of BloodPressure BP = CO X Peripheral vascular resistance CO = SV X HR What determines peripheral vascular resistance?
  • 8.
    Resistance of aTube Porth, Pathophysiology, Concepts of Altered Health States, 7 th ed., 2005, Lippincott, p. 452. Also see p 322, point 2 in Porth, Essentials Big factor!
  • 9.
    Volume & PressureDistribution Porth, 2007, Essentials of Pathophysiology, 2 nd ed., Lippincott, p. 321. Arteriolar tone determines systemic vascular resistance
  • 10.
    Same concept fromLehne Lehne, 2009, Pharmacology for Nursing Care, 7 th ed., Elsevier, p 461
  • 11.
    All Blood VesselsHave 3 Layers Intima - elastic layer Media - smooth muscle for diameter control (innervated by the SNS with alpha receptors) Externa - fibrous and connective tissue for support Porth, 2007, Essentials of Pathophysiology, 2 nd ed., Lippincott, p. 338
  • 12.
    Resistance Arterioles MaintainBlood Pressure Porth, 2007, Essentials of Pathophysiology, 2 nd ed., Lippincott, p. 338 Arteries have abundant smooth muscle. The diameter of the artery/arteriole is determined by the degree of contraction of the smooth muscle, which is mediated by the SNS (alpha receptors).
  • 13.
    Blood Vessels andthe Peripheral Circulation Blood vessels are dynamic structures They constrict and relax to adjust blood flow to meet varying needs of tissues/organs The heart, brain, liver, and kidney require large continuous flow Skin, skeletal muscle require varying flow
  • 14.
    Arteries, Arterioles Elasticityallows for stretching during systole Arterioles have abundant smooth muscle Arterioles are the major resistance vessels for circulatory system and basically determine the systemic vascular resistance Sympathetic fibers innervate arterioles cause them to constrict/relax as needed to maintain BP (alpha receptors)
  • 15.
    Veins, Venules Collectblood from capillaries, carry back to heart Enlarge and store large quantities of blood Contract/expand to accommodate varying amounts Innervated by SNS (alpha receptors) Venous constriction can increase the preload to the heart by conducting stored blood into the vena cava
  • 16.
    Veins Valves preventretrograde flow Incompetent valves in venous varicosities Skeletal muscles help compress veins in “milking manner” up to heart Low pressure system – Pressure in venules is ~10 mm Hg and in the vena cava ~0 mmHg Porth, 2007, Essential of Pathophysiology, 2 nd ed., Lippincott, p. 339.
  • 17.
    Endothelial Cells Endothelialcells line all blood vessels. They are normally quite smooth and permit laminar blood flow. They also form a tight barrier in larger vessels, but in capillaries are more permissive of small molecules exiting and entering the vascular system.
  • 18.
    Capillaries Single cell-thickvessels that connect arterial and venous segments Wall composed of a single layer of endothelial cells surrounded by a basement membrane In most vascular beds, capillaries have fenestrations that allow passage of water and small molecules but not large proteins. Porth, 2007, Essentials of Pathophysiology, 2 nd ed., Lippincott, p. 341.
  • 19.
    Vascular Smooth Muscleand Sympathetic Nervous System Norepinephrine-activated alpha receptors cause calcium channels in vascular smooth muscle to open, which produces vasoconstriction In some vascular beds, beta-2 receptors promote vasodilation by decreasing calcium. C alcium C auses C ontraction in vascular smooth muscle Calcium channel blockers prevent vasoconstriction
  • 20.
    Perfusion of OrgansTissue blood flow to a given organ is regulated on minute-to-minute basis in relation to tissue needs Neural mechanisms regulate CO and systemic vascular resistance (BP) to support local mechanisms Local control includes preferential vasoconstriction or vasodilation mediated by the SNS or by intrinsic mechanisms within the organ.
  • 21.
    Tissue Factors Contributingto Local Control of Blood Flow Factors are released from an organ when it has too much or too little blood flow. Increase blood flow Histamine Decrease blood flow Serotonin
  • 22.
    Endothelial Control ofVascular Smooth Muscle The endothelium produces factors that act on smooth muscle to produce vasoconstriction or vasodilation Vasodilating substances Nitric Oxide Vasoconstricting substances Angiotensin II, Prostaglandins, Endothelins
  • 23.
    Functional Anatomy ofthe Heart Pericardium: Sac around heart Porth, 2007, Essential of Pathophysiology, 2 nd ed., Lippincott, p. 328. A “virtual space” which can become fluid or blood-filled (pericardial effusion).
  • 24.
    Contraction: Actin &Myosin Binding http://www.sci.sdsu.edu/movies/actin_myosin_gif.html Spirito et al., NEJM 336, pg 775, 1997
  • 25.
    Heart Valves KeepBlood Flow Unidirectional Semilunar valves: Control blood flow out of ventricles A ortic valve P ulmonic valve A-V valves : Control blood flow between atria & ventricles T ricuspid valve M itral valve Major function of heart valves: Forward direction of blood flow Porth, 2007, Essentials of Pathophysiology, 2 nd ed., Lippincott, p. 329.
  • 26.
    Cardiac Conduction SystemThe conduction system stimulates the myocardium to contract & pump blood The conduction system controls the rhythm of the heart. Heart has two conduction systems One controls atrial activity One that controls ventricular activity The two systems communicate when the impulse that causes atrial contraction travels to the ventricular system via the A-V node
  • 27.
    SA Node Pacemakerof the heart Impulses originate here Located in posterior wall RA Fires at 60 -100 bpm Rate is determined by the autonomic nervous system (beta-1 receptors increase HR and muscarinic receptors decrease it). Porth, 2007, Essentials of Pathophysiology, 2 nd ed., Lippincott, p. 331.
  • 28.
    AV Node Connectsthe atria & ventricles, provides one way conduction Speed of conduction is determined by the ANS Can assume pacemaker function if SA fails to discharge Fires at 40 -60 bpm Porth, 2007, Essentials of Pathophysiology, 2 nd ed., Lippincott, p. 331.
  • 29.
    Purkinje Fibers Supplythe ventricles Large fibers, rapid conduction for swift & efficient ejection of blood from heart Assume pacemaker of ventricles if AV fails Intrinsic rate is 15-40 bpm Porth, 2007, Essentials of Pathophysiology, 2 nd ed., Lippincott, p. 331.
  • 30.
    ECG Electrical eventsrecorded Electrical events precede mechanical events; know what they represent! P QRS T Porth, 2007, Essentials of Pathophysiology, 2 nd ed., Lippincott, p.331 & 333.
  • 31.
    Cardiac Cycle Termused to describe the rhythmic pumping action of heart Cycle divided into 2 parts Systole : period during which ventricles are contracting Diastole : period during which ventricles are relaxed, filling with blood Simultaneous changes occur in pressure (LA,LV, aorta), ventricular volume, ECG, heart sounds during cardiac cycle
  • 32.
    Porth, 2007, Essential of Pathophysiology, 2 nd ed., Lippincott, p. 334. The Wiggers diagram
  • 33.
    Ventricular Systole Porth,2007, Essentials of Pathophysiology, 2 nd ed., Lippincott, p. 334. Isovolumic (isometric) contraction Closure of AV valves (S1), all valves closed. No change in ventricular volume, ventricles contract. When ventricular pressures > aortic & pulmonary pressures, semilunar valves open, leading to the - Ejection period . Stroke volume ejected. Ventricles contract, then relax. Intraventricular pressures  and become less than pressures in aorta & pulm. artery. Blood from large arteries flows back toward ventricles and aortic/pulmonic valves shut (S2).
  • 34.
    Ventricular Diastole Porth,2007, Essentials of Pathophysiology, 2 nd ed., Lippincott, p. 334. Ventricular relaxation & filling. Isovolumic (isometric) relaxation: Semilunar valves closed, ventricles relax. No change in ventricular volume, but  ventricular pressure until it’s less than atrial pressures. AV valves open, blood from atria enters ventricles -> Rapid filling period . Most ventricular filling in first third of diastole.(S3) During the last third, atria contract (atrial kick).
  • 35.
    Atrial Contraction Lastthird of ventricular diastole Gives additional thrust to ventricular filling Important during tachycardia or when heart disease impairs ventricular filling May not be important in a person with a normal heart, especially at physiologic heart rates. Fourth heart sound (S4), when present, occurs when atria contract
  • 36.
    Definitions Cardiac output(CO) Amount of blood the heart pumps/minute 3.5 - 8.0 L/minute Stroke volume (SV) Amount of blood the heart pumps each beat 70 ml/beat CO = SV x HR CO varies with body activities. CO varies by changes in SV and/or HR
  • 37.
    Heart Rate Frequencywith which blood is ejected from heart As HR  ->  CO HR is increased by activation of beta-1 receptors and decreased by activation of muscarinic receptors on the SA node. BUT as HR  ->  diastolic filling time  diastolic filling time may  SV &  CO Tachycardia can be dangerous because the heart may not have time to fill adequately ->  CO
  • 38.
    Cardiac Output =Stroke Volume x Heart Rate Preload Contractility Afterload
  • 39.
    Stroke Volume ComponentsPreload Ventricular filling (volume) Afterload Resistance to ejection of blood from heart Contractility Pumping function of heart
  • 40.
    Preload (“Volume”) Representsthe volume of blood the heart must pump with each beat Largely determined by venous return and stretch of muscle fibers Venous return 64% of blood volume in veins Venous constriction mediated by alpha-1 receptors
  • 41.
    Preload: Frank-Starling Lawof the Heart Actin, myosin filaments that overlap and create cross bridge attachments leads to contraction of cardiac muscle Porth, 2007, Essentials of Pathophysiology, 2 nd ed., Lippincott, p. 336.
  • 42.
    Implications of theFrank-Starling Law At normal volumes, as preload increases, stretch increases, which increases contractility. CO goes up both because of the increased volume and increased contractility The increase in contractility is independent of the SNS – it is an intrinsic property of the heart. At high volumes, the cardiac muscle is overstretched and contractility decreases. This is usually seen only in patients with heart failure (covered in CVII) who have fluid overload.
  • 43.
    Afterload (“Resistance”) Theamount of pressure the heart must develop during the period of isovolumic contraction to open the aortic and pulmonic valves. Arterial pressures are the major sources of resistance Right ventricle: pulmonary arterial pressure (low) Left ventricle: systemic arterial pressure (high – equal to the diastolic BP in the absence of valve disease) Disease of the aortic or pulmonic valves   resistance Stenosis/narrowing of the valve This means that the heart has to develop an increased pressure to open the diseased valve. Diastolic hypertension also increases the pressure necessary to open the aortic valve.
  • 44.
    Effect of Afterloadon CO Guyton, 2006, Textbook of Medical Physiology, 11th ed.,Saunders, p. 114.
  • 45.
    Implications of theAfterload/CO Curve At normal afterloads, in people with normal hearts, afterload is not an important factor in cardiac output. Normally, preload is a much more important determinant of CO. The normal heart pumps what it gets from the venous system. In people with heart failure (CVII), afterload becomes an important determinant of CO.
  • 46.
    Contractility Ability ofthe heart to change its force of contraction Strongly influenced by number of calcium ions that are available to participate in the contractile process. Determined by biochemical and biophysical properties that govern actin and myosin interactions in myocardial cells (Frank-Starling mechanism). Activation of beta-1 receptors in the ventricles by norepinephrine increases the availability of calcium ions and increases contractility.
  • 47.
    Determinants of BloodPressure BP = CO X Peripheral vascular resistance CO = SV X HR
  • 48.
    Mechanisms of BPRegulation Arterial pressure must remain relatively constant as blood flow shifts from one area of body to another Method by which arterial pressure is regulated depends on whether short-term or long-term adaptation is needed
  • 49.
    Mechanisms of BPRegulation Autonomic nervous system – short-term regulation RAAS (Renin-angiotensin-aldosterone system) – longer term regulation Kidneys – control blood volume as well as the RAAS – a long-term mechanism of blood pressure control.
  • 50.
    The Baroreceptor ReflexBaroreceptors in the aortic arch and carotid artery Autonomic centers in the brainstem Cardiac muscle, cardiac conduction system, and vascular smooth muscle.
  • 51.
    The Sensory Componentsof the Baroreceptor Reflex – Chemo and Stretch Receptors Porth, 2007, Essentials of Pathophysiology, 2 nd ed., Lippincott, p. 364.
  • 52.
    ANS Regulation ofBP – the Baroreceptor Reflex Be sure you know which receptors are where!!! McCance & Heuther, 2002, Pathophysiology: The Biologic Basis for Disease in Adults & Children, Mosby, p.961
  • 53.
    Neurotransmitters Porth, Pathophysiology, Concepts of Altered Health States, 7 th ed., 2005, Lippincott, p. 1151.
  • 54.
    Long-term Regulation ofBP Primarily controlled by kidneys Neural mechanisms act rapidly, but can’t maintain their effectiveness over time Kidneys’ control in long term is thru regulation of Na + and H 2 0 balance RAAS Vasopressin
  • 55.
    Humoral Mechanisms: Renin-angiotensin-aldosteronesystem Porth, 2007, Essentials of Pathophysiology, 2 nd ed., Lippincott, p. 365. MUST KNOW THIS!
  • 56.
    Vasopressin (Antidiuretic Hormone(ADH)) Porth, Pathophysiology, Concepts of Altered Health States, 7 th ed., 2005, Lippincott, p. 756.
  • 57.
    Porth, Pathophysiology,Concepts of Altered Health States, 7 th ed., 2005, Lippincott, p. 756. The ANS and RAAS systems work in concert.
  • 58.
    Which of thefollowing is an important determinant of cardiac output in a normal person? Afterload. Heart rate. Venous return (preload) Total peripheral resistance.
  • 59.
    You assess apatient’s pulse to be 40 bpm. He is not an athlete. Given this HR, the electrical impulses in the heart are probably originating from: SA Node AV Node An ectopic atrial focus Purkinje Fibers
  • 60.
    Angiotensin II causes:Release of aldosterone Vasoconstriction of arterioles Increased arterial blood pressure All of the above
  • 61.
    Disorders of Blood Pressure Regulation: Hypertension and Orthostatic Hypotension
  • 62.
    Orthostatic Hypotension Abnormaldrop in BP on assumption of the standing position Defined as a drop in systolic pressure > 20 mm Hg or drop in diastolic pressure > 10 mm Hg when going from lying to standing In absence of normal circulatory reflexes and/or if blood volume is decreased, blood pools in lower part of the body when the standing position is assumed (decreased venous return), CO  and blood flow to the brain is inadequate  dizziness, syncope (fainting), or both
  • 63.
    Porth, 2007, Essentials of Pathophysiology, 2 nd ed., Lippincott, p. 374 Orthostatic Hypotension
  • 64.
    Causes Reduced bloodvolume (dehydration) (reduced preload) This is the most common cause of dizziness and fainting, especially in young, health people. Drug-induced orthostatic hypotension Impairment of venous return (reduced preload) (Ca 2+ channel blockers) Impairment of the baroreceptor reflex (beta blockers, alpha-1 blockers) Diuretics (reduced preload) Aging – sluggish reflexes, including the baroreceptor reflex Bedrest – deconditioning Disorders of the autonomic nervous system
  • 65.
    Treatment Alleviating causeRehydrate, change meds Help cope with disorder, prevent falls, injury Gradual ambulation (sit on edge of bed, move legs) Avoid venodilation (drinking ETOH; exercise in warm environment) Maintain hydration
  • 66.
    Hypertension Common healthproblem in adults A leading risk factor for cardiovascular disorders (myocardial infarction, heart failure, stroke, vascular disease) More common in young men than young women, blacks compared with whites, in persons from lower socioeconomic groups, and with increasing age Diabetics are more likely to have hypertension and it is more likely to lead to cardiovascular disease than in nondiabetics.
  • 67.
    Hypertension PRIMARY “Essential hypertension” Chronic elevation of BP occurs without evidence of other disease 90-95% of hypertension SECONDARY Elevation of BP occurs from some other disorder Kidney disease Chronic renal failure disorders of adrenocorticoid hormones (pheochromocytoma)
  • 68.
    Hypertension Definitions JNC-VII* (June 2003) “ Prehypertension” (120-139/80-89) Stage I (140-159/90-99) Stage II (160-179/100-109) Stage III (>180/>110) * 7th Report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure
  • 69.
    Constitutional Risk FactorsFamily history Hereditary pattern unclear, genes not identified Age related changes BP higher with advancing age Insulin resistance, metabolic syndrome, diabetes (especially type II) Race African Americans more prevalent, early onset, more severe; greater renal, CV damage Less known about other races
  • 70.
    Lifestyle Risk FactorsDiet high in Na + & saturated fats Obesity Physical inactivity Excessive alcohol consumption Oral contraceptives in predisposed women
  • 71.
    Consequences of HTNUsually related to long term effects of HTN on other organs, “ target organ damage ”. HTN seems to accelerate atherosclerotic vascular disease (covered later today) Heart Left ventricular hypertrophy, coronary artery disease (angina, myocardial infarction), heart failure Brain Stroke or transient ischemic attack Chronic kidney disease Peripheral vascular disease Retinopathy
  • 72.
    Consequences of HTNHeart: LV Hypertrophy  workload of LV (  afterload); LV tries to compensate for  workload. LV hypertrophy is major risk factor for ischemic heart disease, dysrhythmias, heart failure, sudden death
  • 73.
    Consequences of HTNVascular damage Coronary arteries – myocardial infarction (CVII) Peripheral blood vessels – peripheral vascular disease Kidney – renal failure Cerebral blood vessels – stroke
  • 74.
    Diagnosis of HypertensionRepeated BP measurements Average of > 2 readings taken at > 2 visits after an initial screening visit; over several months Laboratory tests, x-rays looking for target organ damage ECG, Urinalysis, Hb, Hct, Na + , K + , Cr, glucose, triglycerides, cholesterol
  • 75.
    Treatment of HypertensionLifestyle modification is the first line of treatment Weight reduction, regular physical exercise, DASH eating plan, reduction of dietary sodium intake, moderation of alcohol intake Pharmacologic treatment Goal: To achieve and maintain systolic BP below 140 mm Hg and diastolic BP below 90 mm Hg
  • 76.
    Lehne, 2009, Pharmacology for Nursing Care, 6 7h ed., Elsevier, p. 500 Sites of Action
  • 77.
    Pharmacologic Treatment DiureticsSympatholytics Beta-adrenergic blockers Alpha-1 adrenergic blockers Centrally-acting alpha-2 agonists Drugs that block norepinephrine release Act on RAAS Renin inhibitor ACE inhibitors Angiotensin II receptor blockers Aldosterone antagonists Others Ca +2 channel blockers Direct-acting vasodilators Adapted from Lehne, 2009, Pharmacology for Nursing Care, 7 th ed., Elsevier, Table 46-5, p. 502
  • 78.
    Pharmacologic Treatment Complianceis a huge issue Lifetime treatment Many of the drugs have unpleasant side effects Many are expensive
  • 79.
    Algorithm for TreatingHypertension Lifestyle modifications Goal BP not met Stage 1 – thiazide diuretic /consider ACEI,ARB, beta blocker, CCB or combination Stage 2 – 2-drug combo (usually a thiazide + ACEI, ARB, beta blocker or CCB Goal BP not met Optimize dosage or add a drug from a different class Continue adding drugs from other classes until goal is achieved Goal BP not met Adapted from Lehne, 2009, Pharmacology for Nursing Care, 7 th ed., Elsevier, p. 507
  • 80.
    Classes of AntihypertensiveDrugs Recommended for Initial Therapy in Patients with High-Risk Comorbid Conditions Adapted from Lehne, 2009, Pharmacology for Nursing Care, 7 th ed., Elsevier, p. 508 Condition Drug Classes Recommended for Initial Therapy of HTN Diuretic Beta Blocker ACEI ARB CCB Aldosterone Antagonist Heart Failure X X X X X Post MI X X X Coronary Artery Disease Risk X X X X Diabetes X X X X X Chronic Kidney Disease X X Recurrent Stroke Prevention X X
  • 81.
    Drugs That AffectBP: Diuretics Lehne, 2009, Pharmacology for Nursing Care, 7 th ed., Elsevier, p. 500
  • 82.
    Classification of DiureticsThiazide diuretics – Hydrochlorothiazide (HCTZ ® ) & chlorthalidone High-ceiling (loop)– Furosemide (Lasix ® ) K + sparing: Non-aldosterone antagonists - Triamterene (Dyrenium ® ) Aldosterone receptor antagonists – Spironolactone (Aldactone) Osmotic diuretics – Mannitol All diuretics indirectly prevent the re-absorption of water in the kidneys!
  • 83.
    Thiazides Lehne, 2009, Pharmacology for Nursing Care, 7 th ed., Elsevier, p. 445 Prevent re-absorption of sodium in the distal tubule.
  • 84.
    Thiazides: hydrochlorthiazide &chlorthalidone Uses: Essential hypertension Often first drug used May be part of multiple-drug therapy Edema Preferred drugs for mobilizing edema associated with mild, moderate heart failure
  • 85.
    Thiazide Diuretics AdverseEffects Hypokalemia Hyponatremia, hypochloremia, dehydration Orthostatic hypotension Avoid in pregnancy if possible May reduce placental perfusion (not for routine use in pregnancy) Nocturia if taken at night Drug Interactions Digoxin -> digoxin toxicity (ALL K + -LOSING DIURETICS) Lithium -> lithium toxicity (ALL DIURETICS!!!) NSAIDS -> Reduced natriuresis/diuresis
  • 86.
    Loop Diuretics Lehne,2009, Pharmacology for Nursing Care, 7 th ed., Elsevier, p. 445 Prevent the re-absorption of sodium from the ascending Loop of Henle.
  • 87.
    Furosemide (Lasix ®)A second-line diuretic for hypertension but has many other uses. Used for pulmonary edema associated with congestive heart failure Edema of hepatic, cardiac, or renal origin unresponsive to less efficacious diuretics Promotes diuresis in renal impairment
  • 88.
    Loop Diuretics: AdverseEffects Hypokalemia Hyponatremia, hypochloremia, dehydration Orthostatic hypotension Ototoxicity Avoid in pregnancy if possible Nocturia if taken at night
  • 89.
    Loop Diuretics: DrugInteractions Digoxin – hypokalemia is dangerous with digoxin Nitrates/other antihypertensives – increased hypotensive effects Other ototoxic drugs (aminoglycoside antibiotics) Lithium – lithium toxicity NSAIDS can attenuate the diuretic effect of furosemide
  • 90.
    Potassium-Sparing Diuretics Lehne,2009, Pharmacology for Nursing Care, 7 th ed., Elsevier, p. 445 Prevent the re-absorption of sodium from the collecting tubule and duct.
  • 91.
    Spironolactone - Aldactone® Hypertension Edema Commonly used in combination with thiazide or loop diuretics Effects are delayed
  • 92.
    Spironolactone (Aldactone ®)Adverse effects Hyperkalemia Avoid use of potassium supplements Synergistic with ACE inhibitors and ARBs Endocrine effects Spironolactone has a steroid structure and can cause a variety of effects similar to steroid hormones, such as gynecomastia and impotence in men, menstrual irregularities, hirsutism, and deepening of the voice in women
  • 93.
    Spironolactone (Aldactone ®)Drug interactions Potassium supplements and salt substitutes are contraindicated ACE inhibitors or ARBs may exacerbate the tendency to hyperkalemia Pregnancy category D because of steroid-like effects on the fetus
  • 94.
    Triamterene Often givenin combination with a thiazide Dyazide = hydrochlorothiazide + triamterene Adverse Effect Hyperkalemia – AVOID K + supplements Drug Interactions ACE Inhibitors/ARBs: Hyperkalemia potential NSAIDS may blunt diuretic effect and indomethacin may precipitate renal failure Take after meals in AM Avoid potassium rich diet items -- bananas, orange juice, salt substitutes (which are likely to be KCl)
  • 95.
    Osmotic Diuretics -MannitolLehne, 2009, Pharmacology for Nursing Care, 7 th ed., Elsevier, p. 445 Prevents re-absorption of water from the proximal tubule.
  • 96.
    Mannitol Must begiven parenterally Therapeutic uses Prophylaxis of renal failure Reduction of intracranial pressure Increased intra-ocular pressure When mannitol is in the bloodstream, before it gets into the renal tubules, it increases the osmotic pressure of the blood and draws edema fluid into the vascular system. Mannitol is filtered into the glomerulus, drawing the excess water with it and holding it in the renal tubules for excretion.
  • 97.
    Osmotic Diuretics AdverseEffects Edema (caused by mannitol leaving the circulation and drawing water into the tissues with it) Administer with extreme caution in heart failure because of its ability to increase vascular volume and overload the heart. Dehydration Orthostatic hypotension Drug Interactions Mannitol is not metabolized, very inert. It has no significant drug interactions
  • 98.
    Drugs Acting onRAAS Lehne, 2009, Pharmacology for Nursing Care, 7 th ed., Elsevier, p. 500 Renin inhibitor
  • 99.
  • 100.
    Renin Inhibitor Renininhibition should prevent all activation of the renin-angiotensin aldosterone system. Only one such drug, aliskiren (Tekturna), is approved for use as monotherapy or in combination with hydrochlorothiazide. Like other drugs that target the RAAS, aliskiren is pregnancy category D because of evidence of fetal harm.
  • 101.
    Porth, 2007, Essential of Pathophysiology, 2 nd ed., Lippincott, p. 365. ACE Inhibitors (ACEI) Captopril, lisinopril, enalapril, and others
  • 102.
    Lehne, 2009, Pharmacology for Nursing Care, 7 th ed., Elsevier, p. 469
  • 103.
    Therapeutic Uses ofACEI Hypertension Heart failure Protective effects in diabetic nephropathy Post MI prophylaxis Prevention of MI, stroke, and death in patients at risk
  • 104.
    Therapeutic Uses ofACEIs: HTN Initial responses: reduced formation of angiotensin II Prolonged therapy: additional reduction in BP Do not interfere with cardiovascular reflexes Do not cause hypokalemia but may contribute to the tendency to hyperkalemia if given with potassium-sparing diuretics. Do not induce lethargy, weakness, sexual dysfunction as other antihypertensives may. REDUCE THE RISK OF CV MORTALITY CAUSED BY HEART FAILURE REDUCE THE RISK OF RENAL FAILURE IN DIABETICS
  • 105.
    ACE Inhibitors: AdverseEffects Bilateral renal artery stenosis is a contraindication because these drugs can precipitate acute renal failure in these patients Dry cough – an effect of increased bradykinin First dose hypotension – Most prominent in patients with very high BP or those on diuretics. Teratogenic – contraindicated in pregnancy Angioedema – due to increased bradykinin, may be very serious
  • 106.
    Westra S andde Jager C. N Engl J Med 2006;355:295 A 75-year-old man presented to the emergency department with diffuse swelling of his tongue that had begun a few hours earlier. He had been taking 25 mg of captopril twice daily for the past 3 years because of hypertension. He was treated with epinephrine, corticosteroids, and antihistamines and the swelling resolved over a three-hour period. The angioedema was likely due to the angiotensin-converting enzyme inhibitor.
  • 107.
    ACE Inhibitors: DrugInteractions Digoxin  Increased digoxin levels Lithium  Increased lithium levels/toxicity K + sparing diuretics  hyperkalemia Potassium supplements  hyperkalemia
  • 108.
    ACE Inhibitors Canbe combined with a thiazide diuretic All are oral except for enalaprilat, which is IV only Patients with renal impairment may need dosage reduction
  • 109.
    Porth, 2007, Essential of Pathophysiology, 2 nd ed., Lippincott, p. 365. Angiotensin II Receptor Blockers (ARBs) Losartan, valsartan, candesartan, and others
  • 110.
    ARB Therapeutic UsesHypertension Reductions in BP = ACEI Heart failure – prevent the progression and improve outcomes Diabetic nephropathy – prevents progression Post-MI prophylaxis Stroke prevention
  • 111.
    ARBs Adverse effectsWell tolerated Do not cause cough Angioedema Fetal harm – contraindicated in pregnancy Renal failure Drug interactions Hypotensive effects are additive with other anti-HTN drugs Do not cause hyperkalemia but may contribute if given with potassium-sparing diuretics
  • 112.
    Porth, 2007, Essential of Pathophysiology, 2 nd ed., Lippincott, p. 365. Aldosterone Antagonists Spironolactone Eplerenone (Inspra) Potassium-sparing diuretics (covered previously as diuretics) Promote Na + & H 2 0 excretion in the collecting tubule & duct
  • 113.
    Drugs That AffectBP: Sympatholytics (Antiadrenergics) Beta blockers Alpha-1 blockers Alpha/beta blockers Centrally acting alpha-2 agonists Adrenergic neuron blockers (inhibit synthesis or release of norepinephrine) Ganglionic blockers (not used, we will not cover)
  • 114.
    Drugs That AffectBP: Sympatholytics (Antiadrenergics) Lehne, 2009, Pharmacology for Nursing Care, 7 th ed., Elsevier, p. 500 Sites of Action
  • 115.
    Beta-Adrenergic Blockers* Widelyused anti-hypertensive drugs Actions in hypertension Blockade of cardiac beta-1 receptors ->↓ HR, contractility -> ↓ CO Suppress reflex tachycardia caused by vasodilators Blockade of beta-1 receptors in JG cells in kidney -> ↓ renin release -> ↓ RAAS mediated vasoconstriction (angiotensin II) and volume expansion (aldosterone) Long-term use   peripheral vascular resistance *Recall from Dr McPherson’s lecture; Lehne Chapter 18
  • 116.
    Beta-Adrenergic Blockers Someblock both beta-1 and beta-2 receptors (nonselective) Some have greater affinity for beta-1 than beta-2 (“cardioselective”) – but the selectivity is not absolute Some are partial agonists – they are said to have “intrinsic sympathomimetic activity” or ISA
  • 117.
    Clinical Pharmacology ofSome Beta Blockers Adapted from Lehne, 2009, Pharmacology for Nursing Care, 7 th ed., Elsevier, p. 167 Generic/trade name ISA Cardioselective (beta 1 > beta 2 ) Acebutolol/Sectal ® + Atenolol/Tenormin ® 0 Esmolol/Brevibloc ® 0 Metolprolol/Lopressor ® Slow release/Toprol XL 0 Nonselective (beta 1 = beta 2 ) Pindolol/Visken ® +++ Propranolol/Inderal ® Slow release/Inderal LA® 0 Nonselective alpha/beta blockers Carvedilol/Coreg ® 0 Labetolol/Normodyne ® or Trandate ® 0
  • 118.
    Therapeutic Uses Adaptedfrom Lehne, 2009, Pharmacology for Nursing Care, 7 th ed., Elsevier, p.168 A – approved; I - investigational Drug HTN Angina Dysrrhy-thmias MI Migraine Stage Fright Heart Failure Cardioselective Acebutolol A I A Atenolol A A I A I I Esmolol I A Metolprolol A A I A I A Nonselective Pindolol A I I Propranolol A A A A A I Nonselective alpha/beta blockers Carvedilol A I A A Labetolol A
  • 119.
    Sympatholytics - Alpha-1antagonists Sites of Action Lehne, 2009, Pharmacology for Nursing Care, 7 th ed., Elsevier, p. 500
  • 120.
    Alpha-1 Antagonists* Doxazosin,terazosin, prazosin and others Block alpha-1 receptors on arterioles and veins  prevent SNS-mediated vasoconstriction  vasodilation   peripheral resistance,  venous return to heart Not used as first line therapy for hypertension Orthostatic hypotension is a big problem Sexual side effects are big reasons for noncompliance Doxazosin, terazosin and tamsulosin (Flomax) used for BPH. *Recall Dr McPherson’s lecture; Lehne Chapter 18
  • 121.
    Centrally Acting Alpha-2Agonists Sites of Action Lehne, 2009, Pharmacology for Nursing Care, 7 th ed., Elsevier, p. 500
  • 122.
    Centrally Acting Alpha-2Agonists Clonidine, methyldopa (agent of choice for chronic hypertension in pregnancy – not for pre-eclampsia) Act within brainstem (alpha-2 receptors) to suppress sympathetic outflow to the heart and blood vessels -> vasodilation,  CO   BP Cause dry mouth, sedation, hemolytic anemia, liver disorders Rebound hypertension if abruptly stopped
  • 123.
    Calcium Channel BlockersDihydropyridines Nifedipine Amlodipine (Norvasc) Promote dilation of arterioles, little effect on veins Non-dihydropyridines Verapamil, diltiazem Promote dilation of arterioles, little effect on veins Also act on heart to slow conduction and decrease contractility
  • 124.
    Lehne, 2009, Pharmacology for Nursing Care, 7 th ed., Elsevier, p. 481 Calcium Channels in the Heart
  • 125.
    Verapamil Blocks Ca+2 channels in arterioles, heart Dilation of peripheral vessels   BP Dilation of coronary arteries   coronary perfusion Blockade at SA node   HR Blockade at AV node   nodal conduction Blockade in myocardium   contractile force Indications Angina pectoris, hypertension, dysrhythmias
  • 126.
    Verapamil: Adverse EffectsConstipation (why?) Dizziness, facial flushing, headache, edema of ankles, feet (why?) Bradycardia, conduction defects (why?)
  • 127.
    Nifedipine and amlodipine(dihydropyridines) Block Ca +2 channels in arterioles Dilation of peripheral vessels ->  BP Dilation of coronary arteries ->  coronary perfusion Do NOT block cardiac Ca +2 channels at therapeutic doses
  • 128.
    Nifedipine & Amlodipine:Indirect(reflex) Effects Lowering BP  baroreceptor reflex ->  firing of SNS to beta receptors in the heart But, nifedipine lacks direct cardiosuppressant actions, cardiac stimulation is unopposed ->  HR,  contractility Net effect is the sum of the direct effect (vasodilation) and the indirect effect (reflex cardiac stimulation)
  • 129.
    Nifedipine & amlodipine:Uses Angina pectoris Vasospastic angina, angina of effort Hypertension Essential hypertension Nifedipine – only use sustained-release formulation for hypertension Take whole, do not crush or chew Amlodipine has a longer half-life than nifedipine and does not have a sustained-release formulation
  • 130.
    Nifedipine & Amlodipine:Adverse Effects Flushing, dizziness, headache, edema Gingival hyperplasia Constipation Do not exacerbate conduction abnormalities Do cause reflex tachycardia ->  cardiac oxygen demand -> angina Give with a beta blocker to counteract this in patients with angina
  • 131.
    Nifedipine blocks Ca+2 channels in arterioles. This results in: Vasoconstriction of peripheral vessels Vasoconstriction of coronary arteries Decrease in HR Dilation of peripheral vessels
  • 132.
    Hypertensive Emergencies (SBP>200 mm Hg or DBP >120 mm Hg) Symptoms of actual or impending end-organ damage Neurological Hypertensive encephalopathy Cerebral vascular accident/cerebral infarction Subarachnoid hemorrhage Intracranial hemorrhage Cardiovascular Myocardial ischemia/infarction Acute left ventricular dysfunction Acute pulmonary edema Aortic dissection Other Acute renal failure/insufficiency Retinopathy Eclampsia Microangiopathic hemolytic anemia
  • 133.
    Sodium nitroprusside-Nitropress ®A very powerful arterial vasodilator No reflex tachycardia Overshoot hypotension is possible but can be correctly quickly by stopping or slowing the infusion Titrate to blood pressure An infusion pump is essential. An arterial line or an automatic blood pressure cuff must be used to check BP continuously.
  • 134.
    Adverse Effects Cyanidepoisoning Likely in pts with liver disease Avoid prolonged rapid infusion Thiocyanate Toxicity Likely when drug given over days CNS effects (disorientation, delirium) Avoid infusions > 3 days; monitor plasma thiocyanate Lehne, 2009, Pharmacology for Nursing Care, 7 th ed., Elsevier, p. 492
  • 135.
    IV Calcium ChannelBlockers Fenoldepam – long half-life Nicardipine – long half life Clevidipine – short half-life, easy to titrate Titrate similarly to sodium nitroprusside All can cause reflex tachycardia and hypotension.
  • 136.
    How do diureticsdecrease blood pressure? Block beta adrenergic receptors Inhibit angiotensin converting enzyme Act on renal tubules to promote water excretion Act as a vasodilator
  • 137.
    Disorders of ArterialCirculation Hyperlipidemia Leading to Atherosclerosis
  • 138.
    Hyperlipidemia Triglycerides, phospholipids,cholesterol classified as lipids; chemical substances insoluble in water but soluble in alcohol. Three types of biological lipids Triglycerides Used as sources for energy metabolism Phospholipids Structural components of lipoproteins, clotting components, myelin sheath, cell membranes Cholesterol Basis of steroid hormones and an important cell membrane component
  • 139.
    Lipoproteins Lipids (cholesterol,triglycerides) insoluble in plasma Encapsulated in lipid transport particles (lipoproteins) composed of phospholipids and embedded proteins Apoproteins are large proteins contained within the phospholipid coat of the lipoprotein Porth, 2007, Essentials of Pathophysiology, 2 nd ed., Lippincott, p. 348.
  • 140.
    Five Types ofLipoproteins Porth, 2007, Essentials of Pathophysiology, 2 nd ed., Lippincott, p. 348. -Of the five, LDLs and HDLs are the most important - As the density of the lipoprotein increases, the proportion of triglycerides decreases and the proportion of cholesterol increases
  • 141.
    Lipoprotein Synthesis &Transport Porth, 2007, Essentials of Pathophysiology, 2 nd ed., Lippincott, p. 349. Synthesis in small intestine, liver Liver important in LDL metabolism; removes LDL via LDL receptors
  • 142.
    HDL “ Goodcholesterol” Carries cholesterol FROM tissues TO liver High HDL prevents atherosclerosis HDLs are scavengers, picking up cholesterol from deposits in the arteries and bringing it back to the liver for disposal HDL inhibits uptake of LDLs into cells Exercise, moderate ETOH  HDLs Smoking, diabetes or metabolic syndrome (sort of a diabetic prodrome)  HDLs
  • 143.
    LDL Familial defectsin LDL receptor – “familial hypercholesterolemia” Inadequate, or defective hepatic uptake of LDL  circulating LDL “ Receptor disease”
  • 144.
    LDL Receptors inLiver Remove LDLs from the Blood Robbins & Cotran Pathologic Basis of Disease (7th ed), 2005, Elsevier, p.158
  • 145.
    Hypercholesterolemia Primary Developsindependent of other causes; defective synthesis of apoproteins, lack of receptors, defective receptors, defects in handling of cholesterol in cell that are genetically determined Secondary Associated with other health problems & behaviors (high fat diet, obesity, diabetes mellitus) Porth, 2007, Essentials of Pathophysiology, 2 nd ed., Lippincott, p. 350. Xanthomas (deposits of cholesterol) develop in certain areas, including the knuckles.
  • 146.
    Diagnosis, Screening Alladults 20 years of age and older should have a fasting lipoprotein profile done every 5 years Total cholesterol, LDL, HDL, TG See Porth, text on page 350-351 for specific recommendations Also Table 49.4 in Lehne
  • 147.
    Classification of LDL,Total, and HDL Cholesterol Cholesterol Level (mg/dL) Classification Total <200 Optimal 200-239 Borderline high > 240 High LDL cholesterol <100 Optimal 100-129 Above optimal 130-159 Borderline high 160-189 High > 190 Very high Adapted from Porth, 2007, Essentials of Pathophysiology, 2 nd ed., Lippincott, p. 350. Cholesterol Level (mg/dL) Classification HDL cholesterol <40 Low > 60 High
  • 148.
    Why are increasedblood lipids so bad? Increased blood lipids, particularly cholesterol, increase the risk of a vascular disease called atherosclerosis. Fatty deposits form in arterial walls This increases the risk of clot formation and occlusion of an artery. Occluded arteries cause myocardial infarctions, stroke, and peripheral vascular disease. Atherosclerosis leads to arteriosclerosis (hardening of the arteries) which increases the risk of aneurysms and other vessel wall problems.
  • 149.
    Atherosclerosis Atheros (glue/paste)Sclerosis (hardening) Formation of fibrofatty lesions (atheromas) in the intimal lining of large and medium sized arteries (aorta, coronaries, carotids, and many others)
  • 150.
    Atherosclerotic Lesions Fattystreak Thin, flat, yellow discolorations that progressively enlarge by becoming thicker and more elevated. Present in children. Precursors to atheromata? Fibrous atheromatous plaque Complicated lesions
  • 151.
    Atheromatous Plaque Porth,2007, Essential of Pathophysiology, 2 nd ed., Lippincott, p. 353 Plaque Complicated Lesion
  • 152.
    Definitions Thrombus =clot Embolus = a clot that breaks off from its initial location and travels through the vascular system. Stenosis = narrowing or closing off of a vessel (or a heart valve). Mural = wall (a mural thrombus is a clot in the wall of a vessel or a chamber of the heart)
  • 154.
    Robbins & Cotran Pathologic Basis of Disease (7th ed), Elsevier, 2005, p.517
  • 156.
    Porth, 2007, Essentials of Pathophysiology, 2 nd ed., Lippincott, p. 352. Atheromas tend to develop at sites of turbulent flow – near branch points As the artheroma develops, it creates more of a constriction, which produces more turbulent flow. See Figure 17.8 in Porth!
  • 157.
    Laminar & TurbulentFlow Porth, 2007, Essentials of Pathophysiology, 2 nd ed., Lippincott, p. 323.
  • 158.
    Risk Factors forAtherosclerosis Age Men > 45 y.o.; women > 55 y.o. (or premature menopause) Family History MI before 55 y.o. in father or before 65 y.o. mother Current cigarette smoking Hypertension (BP > 140/90) Hyperlipidemia Low HDL (< 40 mg/dL) High LDL Diabetes mellitus
  • 159.
    Risk Factors C-reactiveprotein (CRP) Marker of inflammation; better than LDL? Homocysteine Inhibits coagulation, causes endothelial damage, important in initial phases? Serum lipoprotein (a) Part of the LDL; promotes foam cells Infectious agents Chlamydia pneumoniae
  • 160.
    Clinical Manifestations ofVascular Disease Cotran (1999) pg. 499
  • 161.
    Management Reduction inLDL is primary target for cholesterol-lowering therapy, particularly for people at risk for CHD* Age, family history of premature CHD, cigarette smoker, hypertension, low HDL, diabetes mellitus Some evidence that when lipids are lowered, at least with statin drugs, that atheromatous changes regress. *See Porth, Table 17-1, page 351 and Lehne, Table 49-4, p. 551
  • 162.
    Management Dietary changes* calories,  saturated fats,  cholesterol Lifestyle changes  physical activity, smoking cessation, weight loss Pharmacologic treatment * See Lehne, Table 49-6, pg. 556
  • 163.
    Lipid-Lowering Drugs Porth,2007, Essentials of Pathophysiology, 2 nd ed., Lippincott, p. 349. Mechanisms: Affect cholesterol production by liver Remove cholesterol from bloodstream  LDL receptors  Cholesterol absorption from intestine  intravascular conversion of VLDL and IDL to LDL
  • 164.
    Classes of DrugsUsed in Treatment of Hypercholesterolemia HMG-CoA reductase inhibitors (statins) Bile acid-binding resins Cholesterol absorption inhibitor agents Niacin and its congeners Fibric acid derivatives
  • 165.
    Statins Atorvastatin [Lipitor]Fluvastatin [Lescol] Lovastatin [Mevacor] Provastatin [Pravachol] Rosuvastatin [Crestor] Simvastatin [Zocor]
  • 166.
    Statins Beneficial Actions:Reduce cholesterol synthesis in liver  LDL receptors (most important)  LDLs  HDLs  TG Timing: Results within 2 weeks; maximal 4-6 weeks If drug is stopped, serum cholesterol returns to pretreatment levels (lifelong treatment)
  • 167.
    Statins LDL Receptors in Liver ->  LDLs Robbins & Cotran Pathologic Basis of Disease (7th ed), 2005, Elsevier, p.158
  • 168.
    Statins Cardiovascular actionsReduce inflammation at plaque sites Improve endothelial cell function Enhance blood vessel dilation Reduce risk of thrombosis Increased bone formation Enhance osteoblast activity   risk of osteoporosis, fractures
  • 169.
    Statins: Therapeutic UsesHypercholesterolemia Prevention of cardiovascular events MI, stroke, angina Diabetes ADA: Pts > 40 y.o. with total cholesterol > 135 mg/dL- regardless of LDL ACP: All pts with type 2 diabetes with coronary artery disease, even if they don’t have high cholesterol; all adults with type 2 diabetes plus one CV risk factor - even if they don’t have high cholesterol
  • 170.
    Statins: Side EffectsMyopathy/rhabdomyolysis Report unexplained muscle weakness, tenderness Rosuvastatin higher risk Hepatotoxicity Monitor liver enzymes every 6-12 months Avoid use for pts with viral, alcoholic hepatitis
  • 171.
    Statins: Drug InteractionsFibrates and ezetimibe Also  cholesterol, so their activity might be additive to statins Can also cause myopathy, so the danger from that would also be increased Inhibitors of cytochrome P450 like ketoconazole, erythromycin, HIV protease inhibitors, etc., inhibit the metabolism of statins and raise blood levels   risk of adverse effect
  • 172.
    Bile Acid SequestrantsCholestyramine, colestipol, and colesevelam Biologically inert, insoluble in water, cannot be absorbed from GI tract, simply pass through intestine, excreted in feces Absorb bile acids in the intestine and keep them from being reabsorbed into the bloodstream. New bile acids must be synthesized, which requires cholesterol. LDLs are internalized into liver cells as a source of cholesterol. This lowers LDLs. Reduce LDL cholesterol Maximal reduction within one month (20%) LDL levels return to pre-treatment levels when drug is discontinued
  • 173.
    Bile Acid SequestrantsPorth, 2007, Essentials of Pathophysiology, 2 nd ed., Lippincott, p. 349. Prevent the absorption of cholesterol in the intestine
  • 174.
    Bile acid reabsorption (GI)  synthesis in liver   need for cholesterol   LDL receptors Robbins & Cotran Pathologic Basis of Disease (7th ed), 2005, Elsevier, p.158
  • 175.
    Therapeutic Use ReduceLDL cholesterol Drug plus diet ->  LDL by 15-30% Usually combined with statin  LDL by 50%
  • 176.
    Adverse effects Devoidof systemic effects GI symptoms (except colesevelam) Constipation Bloating Indigestion Nausea
  • 177.
    Bile Acid Sequestrants Drug Interactions Decreased absorption of: Warfarin -Acetaminophen Thiazides -Beta blockers Digoxin -Corticosteroids Iron -Thyroid hormones Fat-soluble vitamins A, D, E, and K (except colesevelam) Take oral medications 1 hour before or 4 hours after the bile acid sequestrant.
  • 178.
    Cholesterol Absorption InhibitorsEzetimibe (Zetia ® )
  • 179.
    Ezetimibe (Zetia ®) Mechanism of action Acts on cells in the brush border of the intestine and inhibits cholesterol absorption Blocks absorption of dietary cholesterol and cholesterol secreted in bile Lowers total cholesterol, LDLs, TG and raises HDLs Used as adjunct to diet modification Can be used as monotherapy or with a statin Recent evidence that the combo of ezetimibe and simvastin (Vytorin) actually worsened plaques rather than making them better .
  • 180.
    Ezetimibe (Zetia): Drug Interactions Statins -  risk of liver damage Fibrates – both  the concentration of cholesterol in the bile   the risk of gallstones Bile-acid sequestrants- impair the absorption of ezetimibe Cyclosporine- inhibits metabolism of ezetimibe   its concentration.
  • 181.
    Nicotinic Acid (Niacin)[Niacor, Niaspan] Porth, 2007, Essentials of Pathophysiology, 2 nd ed., Lippincott, p. 349. Decreases production of VLDLs by inhibiting lipolysis in adipose tissue   LDL
  • 182.
    Nicotinic acid (Niacin)Effect on plasma lipoproteins: Reduces triglycerides (20 – 50%) and LDLs (5-25%) Raises HDLs (15-35%) Drug of choice to lower triglyceride levels in patients at risk for pancreatitis. More effective when combined with statin Triple therapy (nicotinic acid, statin, bile-acid sequestrant)  LDL 70% Nicotinic acid is also a B-vitamin, but doses as a vitamin are much smaller than as a lipid-lowering drug.
  • 183.
    Nicotinic Acid: AdverseEffects Intense flushing of the head & neck in nearly all pts– diminishes in several weeks, attenuated with aspirin GI upset – take with food Hepatotoxic – follow liver enzymes Raises blood levels of homocyteine, a substance thought to increase cardiovascular risk. To counteract this, add folic acid supplements. Hyperglycemia – use with caution in diabetics
  • 184.
    Fibric Acid Derivatives(Fibrates) Porth, 2007, Essentials of Pathophysiology, 2 nd ed., Lippincott, p. 349. Gemfibrozil [Lopid] Fenofibrate [Tricor] Increase lipoprotein lipase ->  VLDLs and  TG storage in adipose tissue (  serum TG) Also  HDL No effect on LDL
  • 185.
    Fibric acid derivativesAdverse effects Gallstones – Increase biliary cholesterol saturation -> increase risk of gallstones Myopathy – like the statins, can cause myopathy Heptatotoxicity – like the statins, fibric acid derivatives are hepatotoxic; Monitor liver enzymes Because of overlapping adverse effects, the combo of a statin and a fibric acid derivative should be used with great caution. Pregnancy category C
  • 186.
    Fibric acid derivativesDrug interactions Warfarin – Gemfibrozil increases the efficacy of warfarin by displacing it from protein binding sites. Follow INR closely Use with caution in statins because of the increase in risk of myopathy
  • 187.
    Which of thefollowing drugs are insoluble in water, cannot be absorbed from the GI tract and pass through the intestine? Bile acid sequestrants HMG Co-A reductase inhibitors Fibric acid derivatives Nicotinic acid
  • 188.
    Which of thefollowing drug classes has been shown to reverse athrosclerotic changes? Statins Fibric acid derivatives Bile acid sequestrants Niacin
  • 189.

Editor's Notes

  • #4 Porth pg. 319-320
  • #5 Porth pg 320
  • #6 Lehne pg. 455
  • #7 Porth pg 321
  • #8 Porth pg 322-324
  • #10 Porth pg 320-321; Compliance, distensibility, porth pg 325.
  • #14 Porth pg 337
  • #19 Porth 340-341
  • #22 Pg 342
  • #23 Porth pg 342
  • #24 Poarth pg 326
  • #25 Porth pg 326
  • #26 Porth pg 327
  • #27 Porth pg 328
  • #28 Porth 328
  • #29 Porth 328
  • #30 Porth 328
  • #31 Porth pg 333
  • #32 Porth 334-335
  • #33 Porth 334
  • #34 Porth pg 335.
  • #35 Porth pg 335.
  • #36 Porth 335
  • #41 Lehne pg 456, Porth 326
  • #48 Porth pg 322-324
  • #49 Porth pg 361
  • #50 Lehne pg 457
  • #52 Porth pg 364; Lehne pg 492
  • #53 Porth pg 343, 364
  • #54 Porth pg 344
  • #55 Porth pg 365
  • #56 Porth pg 364
  • #57 Porth pg 365
  • #58 Lehne pg 457 “regulation of arterial pressure”
  • #63 Porth pg 374
  • #64 Porth pg 374-5
  • #65 Porth pg 375
  • #66 Porth pg 375-376
  • #67 Porth pg 366
  • #69 Porth pg 366
  • #70 Porth pg 366
  • #71 Porth pg 366-367
  • #72 Porth pg 367
  • #75 Porth pg 368
  • #76 Porth pg 368, Lehne pg 490-491
  • #77 Lehne pg 492-494 : Re-iterate that thiazides do not affect VSM!
  • #80 Lehne pg 500
  • #81 Lehne 501 - 502
  • #83 Lehne pg 439
  • #84 Lehne pg 441
  • #86 Lehne pg 443
  • #87 Lehne 439: mechanism of action
  • #88 Lehne pg 439
  • #89 Lehne p 440 - incorporate pt/family teaching into these adverse effects
  • #91 Lehne pg 443; compare mechanism of action here for Aladatone and triamterone (p.443 and 444)
  • #92 Lehne pg 443
  • #95 Lehne pg 444
  • #96 Lehne pg 444
  • #97 Lehne pg 444
  • #102 Porth pg 364
  • #103 Lehne pg 464
  • #104 Lehne pg 464-466
  • #105 Lehne pg 464-465
  • #106 Lehne pg 466-467
  • #108 Lehne pg 467
  • #110 Lehne pg 467-468
  • #111 Lehne pg 468
  • #112 Lehne pg 468
  • #113 Lehne pg 469
  • #115 Lehne 495
  • #116 Lehne pg 495-496
  • #121 Lehne pg 498
  • #123 Lehne pg 498;include pt teaching about sedation and no driving, don’t stop med quickly
  • #124 Lehne pg 474
  • #126 Lehne p475
  • #127 Lehne pg 476
  • #129 Lehne pg 477
  • #131 Lehne pg 478
  • #134 Lehne 484-5
  • #135 Lehne pg 485
  • #138 Porth pg 347
  • #140 Porth pg 347
  • #142 Porth pg 348
  • #145 Lehne pg 558
  • #146 Porth 349, 350
  • #147 Porth pg 350
  • #151 Porth pg 352
  • #152 Porth 352
  • #154 N98-305 Pathophys ACS 11/02/11 12:10 PM Histologic studies have characterized the progression of atherosclerotic lesion types. The earliest lesions (from the first decade on) are characterized histologically by isolated foam cells or fatty streaks in the vessel wall. Lesion growth at this stage occurs mainly by lipid accumulation. Intermediate lesions, which may be associated with small extracellular lipid pools, progress to atheroma, which has a core of extracellular lipid. These lesions may be seen starting in the third decade. Starting in the fourth decade, lesions may progress to the fibrous plaque stage, which is characterized by accelerated increases in smooth muscle and collagen. Complicated lesions are characterized by thrombosis, fissure, and hematoma formation. 2 Atherosclerosis Timeline 2 Stary HC, Chander AB, Dinsmore RE, et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. Circulation. 1995;92:1355–1374. Slide 2
  • #155 Porth 352, robbins pg 517
  • #158 Porth pg 323
  • #159 Porth pg 352
  • #160 Porth 352-3
  • #161 Porth 355
  • #162 Porth 350 - 351.
  • #163 Porth pg 351
  • #164 Porth pg 351
  • #165 Proth 351
  • #166 Lehne pg 557
  • #167 Lehne pg 557-8
  • #168 Lehne pg 558
  • #169 Lehne pg 558
  • #170 Lehne pg 559-60
  • #171 Lehne pg 560
  • #172 Lehne pg 561
  • #173 Lehne pg 562
  • #174 Lehne 562
  • #175 Lehne pg 562-563
  • #176 Lehne pg 563
  • #177 Lehne 563
  • #180 Lehne pg 564
  • #182 Lehne 562
  • #183 Lehne 562
  • #184 Lehne pg 562
  • #185 Lehne pg 563